Document:

<PAGE>

                                                                    Exhibit 10.5

                              AMENDED AND RESTATED
                             STOCKHOLDERS AGREEMENT

     THIS AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this "Agreement") is
entered into as of October 17, 2003 by and among Universal Hospital Services
Inc., a Delaware corporation (the "Company"), the JWC Holders (as defined
below), the Halifax Holders (as defined below), the Management Holders (as
defined below) and the Additional Holders (as defined below).

                                    RECITALS

     A.   Upon consummation of the transactions contemplated by the Stock
Purchase Agreement, dated as of September 26, 2003 (the "Purchase Agreement")
and of certain related transactions to be consummated concurrently therewith,
the Stockholders (as defined below) will own (and may hereafter acquire) certain
shares of Common Stock (as defined below) and certain options, warrants,
securities and other rights to acquire from the Company, by exercise,
conversion, exchange or otherwise, shares of Common Stock or securities
convertible into Common Stock.

     B.   The Company and certain of the Stockholders are parties to that
certain Stockholders' Agreement, dated as of February 25, 1998, as amended (the
"Existing Stockholders Agreement").

     C.   The undersigned Stockholders include (i) the holders of a majority of
the Common Stock Equivalents (as defined under the Existing Stockholders
Agreement) held as of the date of this Agreement by the JWC Holders (as defined
under the Existing Stockholders Agreement) and (ii) the holders of a majority of
the Common Stock Equivalents held as of the date of this Agreement by the
Management Holders (as defined under the Existing Stockholders Agreement).

     D.   The Company and the undersigned Stockholders desire to enter into this
Agreement for the purpose of regulating certain aspects of the Stockholders'
relationships with one another and with the Company and in connection therewith
to amend and restate the Existing Stockholders Agreement in its entirety as set
forth herein pursuant to Section 4.2(c) of the Existing Stockholders Agreement.

                                    ARTICLE I

     In consideration of the premises and the mutual promises, representations,
warranties, covenants and conditions set forth in this Agreement, the receipt
and sufficiency of which are acknowledged by all parties to this Agreement, the
parties to this Agreement mutually agree as follows:

<PAGE>

                                    ARTICLE I

                                   Definitions
                                   -----------

     For the purposes of this Agreement, the following terms shall be defined as
follows:

     "Active Trading Market" shall mean the New York or American Stock Exchange
or the National Association of Securities Dealers, Inc.'s National Market System
or Small Capitalization System.

     "Additional Holders" shall mean those Persons listed as Additional Holders
on the signature pages hereof and all Persons that will become Stockholders
after the date hereof and are designated as Additional Holders pursuant to
Section 3.12 hereof.

     An "Affiliate" of a specified Person shall mean a Person who, directly or
indirectly, through one or more intermediaries, controls or is controlled by or
is under common control with the specified Person and, when used with respect to
the Company, shall include any holder of capital stock holding greater than 5%
of the total number of outstanding shares of Common Stock of the Company on a
fully-diluted basis or any officer or director of the Company.

     "Board of Directors" shall mean the Board of Directors of the Company.

     "Business Day" shall mean any day, other than a Saturday, Sunday or legal
holiday, on which banks in New York, New York and Boston, Massachusetts are
permitted to be open for business.

     "Common Stock" shall mean shares of Common Stock, par value $0.01 per
share, of the Company.

     "Common Stock Equivalents" shall mean, as of any date, (a) all shares of
Common Stock outstanding and (b) all options, convertible securities, warrants
and other securities convertible, exchangeable into or redeemable for Common
Stock, which securities are outstanding and vested and/or exercisable within 60
days of the date of measurement. For the purposes of Sections 3.4, 3.5, 3.6,
3.7, 3.8, 3.9, 3.11, 3.12, 3.13, 4.2, 4.3 and 4.4 and Article V, Article VI and
Article VII, Common Stock Equivalents shall mean all shares of Common Stock and
all options, convertible securities, warrants and other securities convertible,
exchangeable into or redeemable for Common Stock, whether or not vested and/or
exercisable.

     "Company Exclusive First Refusal Period" shall have the meaning set forth
in Section 3.2(a).

     "Competitor" shall mean any Person that competes with the Company in any
activity in which the Company is engaged as of the date of determination,
including but not limited to, the outsourcing of medical equipment and provision
of related services.

                                       2

<PAGE>

     "Demand Registration" means the registration of Registrable Securities by
the Company pursuant to the request of a Requesting Holder under Section 4.4.

     "Dragalong Group" shall have the meaning set forth in Section 3.4.

     "Exchange Act" shall mean the Securities Exchange Act of 1934, as amended,
or any successor federal statute thereto, and the rules and regulations of the
SEC promulgated thereunder, all as the same shall be in effect from time to
time.

     "Existing JWC Investors" shall mean, collectively, JWC Equity Partners and
the JWC Equity Partners Co-Investors.

     "Existing Stockholders Agreement" shall have the meaning set forth in
Recital B.

     "GAAP" shall mean the generally accepted accounting principles in the
United States of America, as such principles are changed from time to time,
consistent with those applied in the preparation of the financial statements of
the relevant Person.

     "Halifax Affirmative Vote" shall have the meaning set forth in Section 5.2.

     "Halifax Capital Partners" shall mean Halifax Capital Partners, L.P., a
Delaware limited partnership.

     "Halifax Directors" shall have the meaning set forth in Section 5.1(c).

     "Halifax Holder" shall mean each of those Persons listed as Halifax Holders
on the signature pages hereof and, after the date hereof, shall mean all such
Persons and/or Permitted Transferees of the Halifax Holders, other than those
transferees who qualify as JWC Holders or Management Holders immediately prior
to or upon the relevant Transfer.

     "Halifax Representative" shall have the meaning set forth in Section 7.9.

     "Halifax Securities" means (a) all Common Stock Equivalents beneficially
owned by the Halifax Holders on the date of this Agreement, (b) any Common Stock
Equivalents or any other equity securities of the Company hereafter acquired by
the Halifax Holders, and (c) any securities of the Company issued with respect
to the securities referred to in clause (a) or (b) above by way of a
payment-in-kind, stock dividend or stock split or in connection with a
combination of shares, exchange, conversion, recapitalization, merger,
consolidation or other reorganization.

     "Holder" shall have the meaning set forth in Section 4.1.

                                       3

<PAGE>

     "HSR Act" shall mean the Hart-Scott-Rodino Antitrust Improvements Act of
1976, as amended, or any successor law, and regulations and rules issued
pursuant to that Act or any successor law.

     "Independent Financial Expert" shall mean an independent valuation or
appraisal firm which certifies that it does not (and the directors and officers
of which do not) have a material direct or indirect financial interest in the
Company, any JWC Holder or any Halifax Holder.

     "Independent Third Party" means any Person who, immediately prior to the
contemplated transaction, does not beneficially own five percent (5%) or more of
the Common Stock Equivalents as of the relevant date and who is not an Affiliate
of any such five percent (5%) beneficial owner.

     "Initiating Stockholder" shall have the meaning set forth in Section
3.3(b).

     "Investors" shall mean, collectively, (i) the JWC Investors and (ii) the
Halifax Holders.

     "Involuntary Transfer" shall have the meaning set forth in Section 3.6.

     "Involuntary Transferee" shall have the meaning set forth in Section 3.6.

     "Involuntary Transfer Notice" shall have the meaning set forth in Section
3.7.

     "IRR" shall mean the discount rate (based on a 365-day year) which, when
utilized to calculate the present value (as of the date of this Agreement) of
all of the cash payments and receipts, causes such present value to equal zero.
For purposes of clarification, the XIRR function of Microsoft Excel, or should
this function no longer be available, the equivalent technique for calculating
XIRR, shall be employed to calculate the IRR referenced in this definition. For
purposes of this calculation, "cash payments and receipts" means only the
following amounts: (i) the amount paid by an Investor to purchase the Common
Stock Equivalents held by such Investor or amounts otherwise contributed to the
capital of the Company by such Investor; (ii) the amount of any cash dividends
or distributions on, or amounts paid in redemption of, any Common Stock
Equivalents held by such Investor; and (iii) the Sale Proceeds received by such
Investor.

     "Joinder Agreement" shall mean a joinder agreement substantially in the
form of Exhibit B attached hereto which is entered into pursuant to Section 3.12
hereof.

     "JWC III Co-invest" shall mean JWC Fund III Co-invest LLC.

     "JWC Equity Partners" shall mean J.W. Childs Equity Partners, a Delaware
limited partnership.

     "JWC Equity Partners III" shall mean J.W. Childs Equity Partners III, L.P.,
a Delaware limited partnership.

                                       4

<PAGE>

     "JWC Equity Partners Co-Investors" shall mean each of those Persons listed
as JWC Equity Partners Co-Investors on the signature pages hereof and, after the
date hereof, shall mean all such Persons and/or Permitted Transferees of the JWC
Equity Partners Co-Investors, other than those transferees who qualify as
Halifax Holders or Management Holders immediately prior to or upon the relevant
Transfer.

     "JWC Holders" shall mean each of those Persons listed as JWC Holders on the
signature pages hereof and, after the date hereof, shall mean all such Persons
and/or Permitted Transferees of the JWC Holders, other than those transferees
who qualify as Halifax Holders or Management Holders immediately prior to or
upon the relevant Transfer.

     "JWC Inc." shall mean J.W. Childs Associates, Inc., a Delaware corporation.

     "JWC Investors" shall mean, collectively, (i) JWC Equity Partners III and
(ii) JWC III Co-invest.

     "JWC Representative" shall have the meaning set forth in Section 7.8.

     "JWC Securities" means (a) all Common Stock Equivalents beneficially owned
by the JWC Holders on the date of this Agreement, (b) any Common Stock
Equivalents or any other equity securities of the Company hereafter acquired by
the JWC Holders, and (c) any securities of the Company issued with respect to
the securities referred to in clause (a) or (b) above by way of a
payment-in-kind, stock dividend or stock split or in connection with a
combination of shares, exchange, conversion, recapitalization, merger,
consolidation or other reorganization.

     "Lien" shall mean any lien, mortgage, pledge, security interest, adverse
claim (as defined in the New York Uniform Commercial Code) or other type of
charge or encumbrance of any kind, or any other type of preferential
arrangement, including, without limitation, the lien or retained security title
of a conditional vendor and any easement, right of way or other encumbrance on
title to real property and any financing statement filed in respect of any of
the foregoing.

     "Majority Halifax Holders" shall mean the Person or Persons having
beneficial ownership of a majority of the Common Stock Equivalents held by
Halifax Capital Partners as of the date of determination.

     "Majority JWC Equity Partners Holders" shall mean the Person or Persons
having beneficial ownership of a majority of the Common Stock Equivalents held
by JWC Equity Partners and the JWC Equity Partners Co-Investors as of the date
of determination.

     "Majority JWC III Holders" shall mean the Person or Persons having
beneficial ownership of a majority of the Common Stock Equivalents held by JWC
Equity Partners III and JWC III Co-invest as of the date of determination.

                                       5

<PAGE>

     "Management Holders" shall mean any Person listed as a Management Holder on
the signature pages hereof and shall also include (a) any director, officer,
employee or consultant engaged in a role reasonably similar to that of an
employee of the Company who hereafter becomes a Stockholder, (b) Permitted
Transferees of the Management Holders, unless immediately prior to such Transfer
such transferee was a JWC Holder or a Halifax Holder, and (c) any Person
designated as a Management Holder by the Company on the Joinder Agreement
executed by such Person.

     "Material Transaction" means any material transaction in which the Company
proposes to engage or is engaged, including a purchase or sale of assets or
securities, financing, merger, consolidation, tender offer or any other
transaction that would require disclosure pursuant to the Exchange Act, and with
respect to which the Board of Directors reasonably has determined in good faith
that compliance with this Agreement may reasonably be expected to either
materially interfere with the Company's ability to consummate such transaction
in a timely fashion or require the Company to disclose material, non-public
information prior to such time as it would otherwise be required to be
disclosed.

     "Offeree Percentage" shall mean, as to each offeree, the fraction,
expressed as a percentage, the numerator of which is the total number of Common
Stock Equivalents held by such offeree, and the denominator of which is the
total number of Common Stock Equivalents.

     "Offeree Holder" shall have the meaning set forth in Section 3.2(a).

     "Offeree Holder Acceptance Notice" shall have the meaning set forth in
Section 3.2(a).

     "Offeree Holder Allocation" shall have the meaning set forth in Section
3.2(a).

     "Offered Blocking Securities" shall have the meaning set forth in Section
4.3(b).

     "Offered Securities" shall have the meaning set forth in Section 6.1(a).

     "Offer Period" shall have the meaning set forth in Section 3.2(a).

     "Offering Holder" shall have the meaning set forth in Section 3.2(a).

     "Offeror" shall have the meaning set forth in Section 3.2(a).

     "Original Halifax Holders" shall mean the Halifax Holders as of the date of
this Agreement.

     "Original JWC Holders" shall mean the JWC Holders as of the date of this
Agreement.

     "Original Management Holders" shall mean the Management Holders as of the
date of this Agreement.

                                       6

<PAGE>

     "Participating Offerees" shall have the meaning set forth in Section
3.3(b).

     "Participation Notice" shall have the meaning set forth in Section 3.3(b).

     "Participation Securities" shall have the meaning set forth in Section
3.3(b).

     "Permitted Transfer" shall mean a Transfer that is not a Prohibited
Transfer and is one of the following:

          (a)  a Transfer of any Common Stock Equivalents by any JWC Holder,
Halifax Holder or Management Holder to such Stockholder's spouse, children
(whether natural, step or by adoption), grandchildren (whether natural, step or
by adoption) or parents or to a trust, partnership or limited liability company
solely for the benefit of one or more of any of such Persons; provided, however,
that the Transferring Stockholder shall retain all of the voting rights of such
Transferred Common Stock Equivalents, as trustee or by some other means;

          (b)  a Transfer of Common Stock Equivalents by a JWC Holder to JWC
Inc., JWC Equity Partners or JWC Equity Partners III or to the limited partners,
co-investors, officers, employees or consultants of JWC Inc., JWC Equity
Partners or JWC Equity Partners III, or to a corporation or corporations or to a
partnership or partnerships, limited liability company or companies (or other
entity for collective investment, such as a fund) which is (and continues to be)
an Affiliate of or controlled by, controlling or under common control with JWC
Inc., JWC Equity Partners or JWC Equity Partners III; provided, however, that
the Transferring JWC Holder shall retain all of the voting rights of such
Transferred Common Stock Equivalents;

          (c)  a Transfer of Common Stock Equivalents by a Halifax Holder to The
Halifax Group, L.L.C. or Halifax Capital Partners or to the limited partners,
co-investors, officers, employees or consultants of The Halifax Group, L.L.C. or
Halifax Capital Partners, or to a corporation or corporations or to a
partnership or partnerships, limited liability company or companies (or other
entity for collective investment, such as a fund) which is (and continues to be)
an Affiliate of or controlled by, controlling or under common control with The
Halifax Group, L.L.C. or Halifax Capital Partners; provided, however, that the
Transferring Halifax Holder shall retain all of the voting rights of such
Transferred Common Stock Equivalents;

          (d)  a Transfer of Common Stock Equivalents between or among the JWC
Holders or the Halifax Holders;

          (e)  a Transfer (voluntary or involuntary) of Common Stock Equivalents
between any Stockholder who is a natural person and such Stockholder's guardian
or conservator;

                                       7

<PAGE>

          (f)  a bona fide pledge of Common Stock Equivalents by a JWC Holder or
a Halifax Holder to a bank or financial institution;

          (g)  a Transfer of Common Stock Equivalents by a JWC Holder or a
Halifax Holder to a Management Holder who is not an Affiliate (other than as an
officer, employee, director or stockholder of the Company) of JWC Inc. or The
Halifax Group, L.L.C.; and

          (h)  a Transfer by will or intestacy to the immediate family (as that
term is defined in Rule 16a-1(e) promulgated under the Exchange Act) of a
Stockholder who is a natural person, or, under such will or as ordered by a
probate court, to a trustee or custodian for the benefit or account of any such
member of the Stockholder's immediate family.

No Permitted Transfer shall be effective unless and until the transferee of the
Common Stock Equivalents so transferred executes and delivers to the Company an
executed Joinder Agreement in accordance with Section 3.12 hereof; provided,
however, that the Permitted Transfer to a bank or a financial institution
pursuant to clause (f) above shall be effective upon delivery of the Common
Stock Equivalents and such entity shall not execute and deliver an executed
Joinder Agreement in accordance with Section 3.12 hereof unless and until
foreclosure or similar action by any such pledgee.

     "Permitted Transferee" shall mean, with respect to any Stockholder, any
Person who shall have directly or indirectly acquired and who shall hold any
Common Stock Equivalents pursuant to a Permitted Transfer from that Stockholder.
Notwithstanding the foregoing, a Permitted Transferee shall not include any
Person that is in receivership, bankruptcy, insolvency, dissolution, liquidation
or any similar proceeding or any Person whose incompetence has been established
pursuant to a judicial determination.

     "Person" shall mean an individual, corporation, partnership, limited
liability company, trust, unincorporated association, government or any agency
or political subdivision thereof, or any other entity.

     "Preemptive Offer" shall have the meaning set forth in Section 6.1(a).

     "Preemptive Offer Acceptance Notice" shall have the meaning set forth in
Section 6.1(b).

     "Preemptive Offer Allocation" shall have the meaning set forth in Section
6.1(b).

     "Preemptive Offeree" shall have the meaning set forth in Section 6.1(a).

     "Preemptive Offer Period" shall have the meaning set forth in Section
6.1(a).

     "Primary Shares" shall mean at any time the authorized but unissued shares
of Common Stock or shares of Common Stock held by the Company in its treasury.

                                       8

<PAGE>

     "Prohibited Transfer" shall mean (a) any Transfer of any Subject Security
which (i) may not be effected without registering the securities involved under
the Securities Act (other than pursuant to the registration rights granted in
Article IV of this Agreement), (ii) would require any securities of the Company
to be registered under the Exchange Act (other than pursuant to the registration
rights granted in Article IV of this Agreement) or (iii) is in violation of this
Agreement and (b) prior to the Company's initial Public Offering, any Transfer
of any Subject Security which (x) would result in the assets of the Company
constituting "Plan Assets" as such term is defined in the Department of Labor
regulations promulgated under the Employee Retirement Income Security Act of
1974, as amended, (y) would cause the Company to be controlled by or be under
common control with an "investment company" for purposes of the Investment
Company Act of 1940, as amended or (z) is to a Person that is a Competitor of
the Company (other than Transfers in accordance with Sections 3.4 or 4.2).

     "Public Offering" shall mean the completion of a sale of shares of Common
Stock pursuant to a registration statement which has become effective under the
Securities Act, excluding a registration form relating solely to employee
benefit plans, or a registration form which does not permit secondary sales or
does not include substantially the same information as would be required in a
Form S-1 or Form S-3 Registration Statement (or any successor forms) covering
the sale of Registrable Securities.

     "Purchase Agreement" shall have the meaning set forth in Recital A.

     "Purchase Agreement Closing Date" shall mean the closing date under the
Purchase Agreement.

     "Refused Securities" shall have the meaning set forth in Section 6.1(c).

     "Registrable Securities" shall mean, as of any date, with respect to any
Stockholder, (a) all shares of Common Stock held by such Stockholder as of such
date and (b) all shares of Common Stock that may be acquired as of such date by
such Stockholder upon exercise of Vested Options; provided that, any particular
Registrable Security shall cease to be a Registrable Security when (i) a
registration statement (other than a registration statement on Form S-8) with
respect to the sale or exchange of such security shall have become effective
under the Securities Act and such security shall have been disposed of in
accordance with such registration statement, (ii) a registration statement on
Form S-8 with respect to such security shall have become effective under the
Securities Act, (iii) such security shall have been sold or acquired in a Rule
144 Transaction, or (iv) such security (once issued) has ceased to be
outstanding.

     "Representative" shall mean the JWC Representative or the Halifax
Representative, as the case may be.

     "Rule 144 Transaction" means a transfer of Common Stock complying with Rule
144 under the Securities Act as such rule or a successor thereto is in effect on
the date of such transfer.

                                       9

<PAGE>

     "Sale of the Company" means the consummation of a transaction, other than a
Public Offering, whether in a single transaction or in a series of related
transactions that are consummated contemporaneously (or consummated pursuant to
contemporaneous agreements), with an Independent Third Party or a group of
Independent Third Parties pursuant to which such party or parties (a) acquire
(whether by merger, stock purchase, recapitalization, reorganization,
redemption, issuance of capital stock or otherwise) more than 50% of the Common
Stock Equivalents as of such date or (b) acquire assets constituting all or
substantially all of the assets of the Company.

     "Sale Proceeds" shall mean the aggregate cash proceeds (if any) received by
an Investor as a result of the consummation of a Sale of the Company pursuant to
Section 4.2 hereof.

     "Sale Request" shall have the meaning set forth in Section 3.4(a).

     "Schedule of Stockholders" shall refer to the Schedule of Stockholders
attached hereto as Exhibit A.

     "SEC" shall mean the Securities and Exchange Commission or successor agency
or commission of the United States federal government.

     "Securities Act" shall mean the Securities Act of 1933, as amended, or any
successor federal statute thereto, and the rules and regulations of the SEC
promulgated thereunder, all as the same shall be in effect from time to time.

     "Stockholder" shall mean any party hereto other than the Company, including
any Person who hereafter becomes a party to this Agreement pursuant to Section
3.12 hereof.

     "Stockholder Group" shall mean any of (a) the JWC Holders, taken as a
group, (b) the Halifax Holders, taken as a group, (c) the Management Holders,
taken as a group, or (d) the Additional Holders, taken as a group. The Company
shall not in any case be deemed to be a member of any Stockholder Group (whether
or not the Company holds or repurchases any Common Stock Equivalents).

     "Stock Option Agreement" shall mean any stock option agreement between the
Company and an employee, director, officer or consultant thereof.

     "Subsidiary" with respect to any Person (the "parent") shall mean any
Person of which such parent, at the time in respect of which such term is used,
(a) owns directly or indirectly more than 50% of the equity or beneficial
interest, on a consolidated basis, or (b) owns directly or controls with power
to vote, indirectly through one or more other Subsidiaries, shares of capital
stock or beneficial interests having the power to cast at least a majority of
the votes entitled to be cast for the election of directors, trustees, managers
or other officials having powers analogous to those of directors of a
corporation. Unless

                                       10

<PAGE>

otherwise specifically indicated, when used herein, the term Subsidiary shall
refer to a direct or indirect Subsidiary.

     "Third Party" shall mean any Person other than the Company.

     "Transfer" shall mean to transfer, sell, assign, pledge, hypothecate, give,
grant or create a security interest in or Lien on, place in trust (voting or
otherwise), assign an interest in or in any other way encumber or dispose of,
directly or indirectly and whether or not by operation of law or for value, any
of the Common Stock Equivalents.

     "Transfer Notice" shall have the meaning set forth in Section 3.2(a).

     "Transfer Offer" shall have the meaning set forth in Section 3.2(a).

     "Transfer Stock" shall have the meaning set forth in Section 3.2(a).

     "Transferred Securities" shall have the meaning set forth in Section 3.6.

     "Unmatured Transfer Shares" shall have the meaning set forth in Section
3.2(c).

     "Unmatured Transfer Shares Anniversary" shall have the meaning set forth in
Section 3.2(c).

     "Unpurchased Preemptive Shares" shall have the meaning set forth in Section
6.1(b).

     "Unpurchased Shares" shall have the meaning set forth in Section 3.2(a).

     "Vested Options" shall mean, as of any date, options, securities and other
rights to acquire from the Company, by exercise, conversion, exchange or
otherwise, shares of Common Stock or securities convertible into Common Stock,
which are vested and exercisable within 60 days of such date of measurement.

     "Voting Stock" shall mean the Common Stock, Common Stock Equivalents and
any other securities of the Company entitled to vote at a meeting of the
Stockholders, including, but not limited to, with respect to the election of the
Board of Directors.

                                       11

<PAGE>

                                   ARTICLE II

               Rights With Respect To The Common Stock Equivalents
               ---------------------------------------------------

     2.1  Limited Rights of Transfer.
          --------------------------

          (a)  No Transfers. Except for the JWC Holders, no Stockholder shall
Transfer all or any part of the Common Stock Equivalents at the time held by
such Stockholder. Subject to Section 3.1(b), no Transfer of or attempt to
Transfer any Common Stock Equivalents in violation of the preceding sentence
shall be effective or valid for any purpose.

          (b)  Exceptions. Notwithstanding Section 3.1(a), a Transfer may be
effectively and validly made hereunder if such Transfer is not a Prohibited
Transfer and is either (i) a Permitted Transfer, (ii) made pursuant to the
demand sale and registration rights granted under Article IV hereof, (iii) made
pursuant to and/or following a Public Offering, (iv) made pursuant to Sections
3.2, 3.3 (as a Participating Offeree) or 3.4, or (v) made with the written
consent of (A) either (w) the holders of a majority of the Common Stock
Equivalents at the time held by the JWC Holders or (x) the JWC Representative
and (B) either (y) the holders of a majority of the Common Stock Equivalents at
the time held by the Halifax Holders or (z) the Halifax Representative.

          (c)  Validity of Transfers; Joinder Agreement. Notwithstanding any
other provision of this Agreement, no Transfer of any Common Stock Equivalents
shall be effective or valid if such Transfer constitutes a Prohibited Transfer,
or unless and until the transferee executes and delivers to the Company a
Joinder Agreement in accordance with Section 3.12 hereof.

     2.2  Right of First Refusal.
          ----------------------

          (a)  Notice of Offer. If (i) at any time prior to the Company's
initial Public Offering, any Halifax Holder, Management Holder, Additional
Holder or any of their Permitted Transferees (the "Offering Holder") receives a
bona fide offer to purchase any or all of such Offering Holder's Common Stock
Equivalents, other than unexercised stock options (such Common Stock
Equivalents, the "Transfer Stock"), from any Third Party, other than to a
Permitted Transferee and other than pursuant to Sections 3.3 or 3.4, or the
demand sale and registration rights granted under Article IV of this Agreement
(such Third Party, the "Offeror"), and (ii) such Offering Holder wishes to
accept such offer (a "Transfer Offer"), then the Offering Holder shall cause the
Transfer Offer to be reduced to writing and shall provide a notice containing
the offer to purchase specified below (the "Transfer Notice") to the Company and
the Company shall deliver a copy of any such Transfer Notice to each JWC Holder
and Halifax Holder (collectively, the "Offeree Holders") promptly upon its
receipt thereof. The Transfer Notice shall be accompanied by a true and correct
copy of the Transfer Offer (which shall identify in reasonable detail the
Offeror, the number of shares of Transfer Stock, the price contained in the
Transfer Offer and all other material terms and conditions of the Transfer
Offer). The Transfer Notice shall constitute an irrevocable

                                       12

<PAGE>

offer to sell all, but not less than all, of the Transfer Stock to the Company
and to the Offeree Holders within 40 days of receipt by the Company of the
Transfer Notice (the "Offer Period"). During the Offer Period, subject to the
limitation in the next sentence, any combination of the Company and/or the
Offeree Holders will have the right and option to purchase all, but not less
than all, of the Transfer Stock at a price equal to the price, and upon the same
terms, as contained in the Transfer Offer. During the first 15 days of the Offer
Period (the "Company Exclusive First Refusal Period"), the Company shall have
the exclusive right and option to purchase all of the Transfer Stock. In the
event that the Company elects not to purchase all of the Transfer Stock, it
shall deliver to each Offeree Holder written notice of such election on or
before the last day of the Company Exclusive First Refusal Period, which notice
shall set forth the portion of the Transfer Stock that such Offeree Holder is
entitled to purchase, which portion shall be equal to the product of (i) such
Offeree Holder's Offeree Percentage multiplied by (ii) the sum of (A) the number
of shares of Transfer Stock set forth in the Transfer Notice less (B) the number
of shares of Transfer Stock, if any, the Company elected to purchase in
accordance with this Section 3.2(a) (the "Offeree Holder Allocation"). Each
Offeree Holder shall then have the right to purchase up to its Offeree Holder
Allocation of the total number of shares of Transfer Stock proposed to be
Transferred by delivering to the Offering Holder a written notice (the "Offeree
Holder Acceptance Notice") (with a copy thereof to the Company) within 15 days
following the expiration of the Company Exclusive First Refusal Period (the
"Offeree Holders First Refusal Period"). In the event that any Offeree Holder
elects not to acquire shares of Transfer Stock equal to its Offeree Holder
Allocation, such Offeree Holder shall deliver to the other Offeree Holders
written notice of such election (with a copy to the Company) on or before the
last day of the Offeree Holders First Refusal Period, which notice shall include
the number of shares not elected to be purchased by such Offeree Holder (the
"Unpurchased Shares"). Each of the Offeree Holders electing to purchase shares
of Transfer Stock equal to its Offeree Holder Allocation (collectively, the
"Exercising Offeree Holders") may elect, by written notice to the Company and
the Offering Holder within 10 days following the expiration of the Offeree
Holders First Refusal Period, to purchase all or a portion of the Unpurchased
Shares. If the Exercising Offeree Holders deliver notices electing to purchase
more than the total number of Unpurchased Shares, the Unpurchased Shares shall
be allocated on a pro-rata basis based on the number of Common Stock Equivalents
held by such Exercising Offeree Holders. For the avoidance of doubt, unless the
Offering Holder shall have consented to the purchase of fewer than all of the
Transfer Stock by the Company and/or the Offeree Holders (as the case may be),
neither the Company nor any Offeree Holder, nor any combination of the Company
and any Offeree Holder, may purchase any Transfer Stock pursuant to the
foregoing provisions, unless all of the Transfer Stock is to be so purchased
(whether by the Company, the Offeree Holders, or any combination thereof).
Notwithstanding any other provision of this Agreement, unless otherwise agreed
to by (y) either (1) at least 50% of the Common Stock Equivalents held by the
JWC Holders or (2) the JWC Representative and (z) either (1) 50% of the Common
Stock Equivalents held by the Halifax Holders or (2) the Halifax Representative,
no Management Holder or Additional Holder may Transfer their Common Stock
Equivalents in exchange for consideration other than cash.

          (b)  Closing of Transfer Stock. If, during the Offer Period, the
Company, or any combination of the Company and the Offeree Holders, has accepted
the offer contained in the Transfer

                                       13

<PAGE>

Notice, then, subject to Section 3.2(c), the closing of the purchase of such
Transfer Stock shall take place at the principal offices of the Company either
(i) within 15 days of such acceptance or (ii) if applicable, the first Business
Day after the waiting period applicable to the purchase and sale of such
Transfer Stock under the HSR Act has expired or been terminated. At such
closing, the Company and/or the Offeree Holders, as applicable, and/or its or
their designees, as the case may be, shall deliver a certified check or checks
calculated at the price set forth in the Transfer Notice to the Offering Holder
against delivery of certificates and/or other instruments representing the
Transfer Stock, together with stock or other appropriate powers duly endorsed
with respect to the Transfer Stock, free and clear of all Liens (other than
pursuant to securities laws, this Agreement or a Stock Option Agreement). All of
the foregoing deliveries will be deemed to be made simultaneously and none shall
be deemed completed until all have been completed.

          (c)  Unmatured Transfer Shares. Notwithstanding the foregoing, with
respect to any shares of Common Stock which, as of the date the Company accepted
the offer contained in the Transfer Notice, have not been owned by the Offering
Holder for more than six months ("Unmatured Transfer Shares"), the closing with
respect to such Unmatured Transfer Shares being purchased by the Company shall
occur on a date selected by the Company, but in no event earlier than the
six-month anniversary of the date on which such Unmatured Transfer Shares were
purchased by such Offering Holder (the "Unmatured Transfer Shares Anniversary")
and no later than the 15th day after the Unmatured Transfer Shares Anniversary.
Between the date on which the Company or any of its Affiliates accepts the offer
contained in the Transfer Notice and the closing with respect to such Unmatured
Transfer Shares being purchased by the Company or any of its Affiliates, the
Offering Holder shall not Transfer such Unmatured Transfer Shares other than
pursuant to Section 3.4 hereof.

          (d)  Completion of Sale to Third Party. If the Company and/or the
Offeree Holders has/have not accepted the offer contained in the Transfer Notice
in writing as to all the Transfer Stock covered thereby during the Offer Period,
or if the closing of the purchase of the Transfer Stock has not occurred within
the period specified in Section 3.2(b), and Section 3.4 does not apply to such
Transfer, then during the next 60 days, the Offering Holder may sell the
Transfer Stock to the Offeror upon the terms and conditions, including price,
which are no more favorable, in the aggregate, to such Offeree or less favorable
to the Holder than those contained in the Transfer Notice. Promptly after any
sale pursuant to this Section 3.2, the Offering Holder shall furnish such
evidence of the completion (including time of completion) of such sale and of
the terms thereof as the Company may reasonably request. If the Offering Holder
has not completed the sale of the Transfer Stock during the applicable period
referred to above, such Offering Holder shall no longer be permitted to sell
such shares pursuant to this Section 3.2 without again fully complying with the
provisions of this Section 3.2 and all the restrictions on sale, transfer or
assignment contained in this Agreement shall again be in effect with respect to
the Transfer Stock.

                                       14

<PAGE>

     2.3  Tagalong.
          --------

          (a)  Trigger of Tag-Along Right. No JWC Holder shall Transfer any
Common Stock Equivalents to a Third Party (other than a Permitted Transferee and
other than pursuant to Section 3.4 or the demand sale and registration rights
granted under Article IV of this Agreement) in one or a series of related
transactions without complying with the terms and conditions set forth in this
Section 3.3; provided, however, that the JWC Holders shall be permitted to
Transfer up to 5%, in the aggregate, of the number of Common Stock Equivalents
held by the Original JWC Holders as of the date of this Agreement without
compliance with this Section 3.3; provided further, however, that this Section
3.3 shall not in any way limit or affect the restriction contained in Section
3.1(c).

          (b)  Notice of Tag-Along Sale. Any JWC Holder (the "Initiating
Stockholder") desiring to Transfer Common Stock Equivalents subject to the
restriction in this Section 3.3 shall give not less than 10 Business Days' prior
written notice of such intended Transfer to each other Stockholder
("Participating Offerees") and to the Company. Such notice (the "Participation
Notice") shall set forth the material terms and conditions of such proposed
Transfer, including the name of the prospective transferee, the number of Common
Stock Equivalents proposed to be transferred (the "Participation Securities") by
the Initiating Stockholder, the purchase price per share proposed to be paid
therefor and the payment terms and type of Transfer to be effectuated. Within 10
Business Days following the delivery of the Participation Notice by the
Initiating Stockholder to each Participating Offeree and to the Company, each
Participating Offeree shall, by notice in writing to the Initiating Stockholder
and to the Company, have the opportunity and right to sell Common Stock
Equivalents to the purchasers in such proposed Transfer (upon the same terms and
conditions as the Initiating Stockholder) and to include in such proposed
Transfer an amount of Common Stock Equivalents representing the same proportion
of the aggregate Common Stock Equivalents owned by such Participating Offeree as
is proposed to be Transferred by the Initiating Stockholder (relative to the
aggregate Common Stock Equivalents owned by such Initiating Stockholder).

          (c)  Closing of Tag-Along Sale. At the closing of any proposed
Transfer in respect of which a Participation Notice has been delivered, the
Initiating Stockholder, together with all Participating Offerees that have
timely and properly elected to sell Common Stock Equivalents pursuant to Section
3.3(b), shall execute and deliver such agreements for the sale of such Common
Stock Equivalents and such other agreements, instruments and certificates as the
Initiating Stockholder shall execute and deliver in connection with such
Transfer and deliver to the proposed transferee certificates and/or other
instruments representing the Common Stock Equivalents to be sold, free and clear
of all Liens (other than pursuant to securities laws, this Agreement or a Stock
Option Agreement), together with stock or other appropriate powers duly endorsed
therefor, and shall receive in exchange therefor the consideration to be paid or
delivered by the proposed transferee in respect of such Common Stock Equivalents
as described in the Participation Notice. All Common Stock Equivalents acquired
by a Third Party pursuant to this Section 3.3 from the applicable JWC Holders
and/or the Participating Offerees shall be held by such acquiring Third Party
subject to the terms and conditions of this Agreement or be free from such terms
and conditions, in each case, as the transferring JWC Holder and the acquiring
Third Party shall agree.

                                       15

<PAGE>

          (d)  Termination. If, at the end of 90 days following the receipt by
the Stockholders of a Participation Notice, the Initiating Stockholder has not
completed the proposed Transfer, it shall be necessary for a new and separate
Participation Notice to be furnished and the terms and provisions of this
Section 3.3 to be separately complied with in order to consummate such Transfer
pursuant to this Section 3.3, unless the failure to complete such Transfer
resulted from any failure by any Stockholder to comply in any material respect
with the terms of this Section 3.3.

          (e)  Exclusion for Compliance with Other Provisions. The provisions of
this Section 3.3 shall not apply to (i) any Transfer pursuant to a Public
Offering or, following a Public Offering, pursuant to an ordinary course
brokerage transaction or (ii) any Transfers pursuant to Section 3.4 hereof.

     2.4  Dragalong.
          ---------

          (a)  Grant of Dragalong Right. If one or more of the JWC Holders (the
"Dragalong Group") determine to sell or exchange (in a sale or exchange of
securities of the Company or in a merger, consolidation or other business
combination or any similar transaction) in one or a series of related bona fide
arms-length transactions to an unaffiliated Third Party (and not pursuant to a
Permitted Transfer or the registration rights granted under Article IV of this
Agreement) at least 50% of the Common Stock Equivalents (which defined term
shall, for purposes of this Section 3.4, include all Common Stock Equivalents
regardless of vesting or exercisability) at the time held by the JWC Holders,
then upon 10 days' prior written notice from the Dragalong Group to the other
Stockholders, which notice shall include reasonable details and all material
terms of the proposed sale or exchange, including the proposed time and place of
closing and the form and amount of consideration to be received by the
Stockholders (such notice being referred to as the "Sale Request"), each other
Stockholder shall be obligated to, and shall sell, transfer and deliver, or
cause to be sold, transferred and delivered, to such Third Party the proportion
of such Stockholder's Common Stock Equivalents as is being sold by the Dragalong
Group in the same transaction at the closing thereof (and shall (i) execute and
deliver such agreements for the purchase of such Common Stock Equivalents and
such other agreements, instruments and certificates as the members of the
Dragalong Group shall execute and deliver in connection with such proposed
transaction and (ii) deliver certificates and/or other instruments representing
the proportion of such Stockholder's Common Stock Equivalents being sold,
together with stock or other appropriate powers therefore duly executed, at the
closing, free and clear of all Liens (other than pursuant to securities laws,
this Agreement or a Stock Option Agreement)), and each Stockholder shall receive
upon the closing of such transaction the same consideration per Common Stock
Equivalent as shall be payable to the members of the Dragalong Group (in the
case of options, warrants or similar Common Stock Equivalents, subject to
subtraction of the exercise price).

          (b)  Required Indemnification. Each Stockholder shall be severally
obligated to join on a pro rata basis (based on such Stockholder's pro rata
portion of the net proceeds paid by such Third Party) in any indemnification
that is to be provided in connection with such transaction; provided that no

                                       16

<PAGE>

Stockholder shall be obligated in connection with such transaction to agree to
indemnify or hold harmless the Third Party with respect to an amount in excess
of the net cash proceeds paid to such Stockholder in connection with such
transaction. All Stockholders will bear their pro rata portion of the costs and
expenses incurred in connection with such transaction to the extent such costs
are incurred for the benefit of all Stockholders and are not otherwise paid by
the Company or the Third Party.

          (c)  Further Assurances in the Event of a Dragalong. Each Stockholder
agrees that, in such Stockholder's capacity as a stockholder of the Company,
such Stockholder shall vote, or grant proxies relating to the Common Stock at
the time held by such Stockholder to vote, all of such Stockholder's Common
Stock in favor of any sale or exchange of securities of the Company or any
merger, consolidation, recapitalization, reorganization or other business
combination or any similar transaction pursuant to Section 3.4(a) hereof if, and
to the extent that, approval of the Company's stockholders is required in order
to effect such transaction.

          (d)  Termination. If, at the end of 90 days following the receipt by
the Stockholders of a Sale Request, the Dragalong Group has not completed the
transaction, (i) each Stockholder shall be released from its obligation under
the Sale Request, (ii) the Dragalong Group shall return to each Stockholder all
previously delivered certificates evidencing unsold Common Stock Equivalents and
all related powers of attorney and instruments of transfer, if any, and (iii) it
shall be necessary for a new and separate Sale Request to be furnished and the
terms and provisions of this Section 3.4 to be separately complied with in order
to consummate such transaction pursuant to this Section 3.4, unless the failure
to complete such transaction resulted from any failure by any Stockholder to
comply in any material respect with the terms of this Section 3.4.

     2.5  No Other Proxies, Voting or Other Stockholder Agreements. Except for
JWC Holders and the Halifax Holders, no Stockholder shall grant any proxy or
enter into or agree to be bound by any voting trust with respect to any Common
Stock Equivalents other than as set forth in this Agreement. No Stockholder
shall enter into any stockholders agreements or arrangements of any kind with
any Person with respect to any of the Common Stock Equivalents on terms which
conflict with the provisions of this Agreement (whether or not such agreements
and arrangements are with other Stockholders or holders of Common Stock
Equivalents that are not parties to this Agreement), including but not limited
to, agreements or arrangements with respect to the acquisition, disposition or
voting of Common Stock Equivalents inconsistent herewith.

     2.6  Involuntary Transfers are Subject to this Agreement. Except as
otherwise provided in this Agreement, in the event of an Involuntary Transfer
(as defined in the following sentence) of any Common Stock Equivalents (the
"Transferred Securities") of any Stockholder to any Person, the transferee,
including, without limitation, any and all transferees and subsequent
transferees of the initial transferee (the "Involuntary Transferee"), shall take
and hold the Transferred Securities subject to this Agreement and to all of the
obligations of, and restrictions imposed hereby upon, the transferor Stockholder
and shall comply with this Agreement. As used in this Agreement, the term
"Involuntary Transfer" shall mean any

                                       17

<PAGE>

transaction, proceeding or action by or in which the relevant Stockholder is
involuntarily deprived or divested of any right, title or interest in or to any
of such Stockholder's Common Stock Equivalents (including, without limitation, a
seizure under levy of attachment or execution, a foreclosure under a pledge of
Common Stock Equivalents, a Transfer to a trustee in bankruptcy or receiver or
other officer or agency, a Transfer to a state or to a public officer or agency
pursuant to a statute pertaining to escheat or abandoned property, or a Transfer
pursuant to a divorce proceeding ).

     2.7  Required Notice in the Event of Involuntary Transfer. In the event
of an Involuntary Transfer, the Stockholders and the Company shall not take any
action to approve any such Involuntary Transfer not in accordance with this
Section, and the transferor Stockholder (or, if it fails to do so, the
Involuntary Transferee) shall forthwith give notice (the "Involuntary Transfer
Notice") to the Company stating (i) when the Involuntary Transfer occurred or is
to occur, (ii) the circumstances alleged to require such Involuntary Transfer,
(iii) the number of Common Stock Equivalents involved and (iv) the name, address
and capacity of the Involuntary Transferee.

     2.8  Option Granted in the Event of Involuntary Transfer. If an Involuntary
Transfer of the Common Stock Equivalents of any Stockholder occurs, the Company
and its designees shall have the same rights of first refusal with respect to
the Transferred Securities as if the Involuntary Transfer had been a proposed
voluntary Transfer by the transferor Stockholder governed by Section 3.2 except
that: (i) the periods within which such right must be exercised shall run from
the date the Involuntary Transfer Notice is given in accordance with this
Agreement; (ii) such rights shall be exercised by notice to the Involuntary
Transferee rather than to the Offering Holder and (iii) the per share price for
the Transferred Securities shall be equal to their fair market value as of the
date the Involuntary Transfer Notice is given, as determined in good faith by
the Board of Directors of the Company. The closing of any purchase of
Transferred Securities pursuant to this Section shall be in accordance with the
procedures set forth in Section 3.2.

     2.9  Right of First Refusal in the Event of Involuntary Transfers . Without
limiting the effects of Sections 3.6 or 3.11 hereof, if the provisions of
Section 3.8 are held to be unenforceable for any reason with respect to any
particular Involuntary Transfer of Transferred Securities, or if the right of
first refusal is not exercised with respect to such Involuntary Transfer, the
Company and its designees shall have a right of first refusal in accordance with
Section 3.2 if the Involuntary Transferee subsequently obtains a bona fide offer
for and desires to Transfer such Transferred Securities, in which case all
references to the "Offering Holder" in Section 3.2 shall be deemed to include
and refer to the Involuntary Transferee.

     2.10 (a)  Purchase for Investment; Legend on Certificate. Each Stockholder
acknowledges that all of the securities of the Company held by such Stockholder
are being (or have been) acquired for investment and not with a view to the
distribution thereof and that no Transfer of any such securities (including the
Common Stock for which such securities may be exercisable or exchangeable or
into which such securities may be convertible) may be made except in compliance
with applicable federal and state securities laws. All the certificates or other
instruments representing any of such securities (including the Common Stock for
which such securities may be exercisable or exchangeable or into which such
securities

                                       18

<PAGE>

may be convertible) which are now or hereafter held by any Stockholder shall be
subject to the terms of this Agreement and shall have endorsed in writing,
stamped or printed, thereon the following legends:

     "THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS
     AND CONDITIONS OF AN AMENDED AND RESTATED STOCKHOLDERS AGREEMENT DATED AS
     OF OCTOBER 17, 2003, AS AMENDED FROM TIME TO TIME, A COPY OF WHICH IS ON
     FILE WITH AND AVAILABLE FROM THE SECRETARY OF THE COMPANY."

     "THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE
     WERE NOT REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE
     SECURITIES LAWS OF ANY STATE OR JURISDICTION, AND THE SECURITIES
     REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD, ASSIGNED, TRANSFERRED,
     PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH THE REQUIREMENTS
     OF SUCH LAWS."

          (b)  The certificates evidencing the securities of the Company
acquired by any Stockholder shall also bear any legend required under any
applicable state securities laws. Absent an effective registration statement
under the Securities Act covering the Transfer of the securities of the Company
held by a Stockholder, no Stockholder shall Transfer any securities of the
Company unless such Transfer is exempt from the registration and prospectus
delivery requirements of the Securities Act and has been registered or qualified
under (or is exempt from the registration and qualification requirements of) any
applicable state securities laws. Each Stockholder consents to the Company
making a notation on its records or giving instructions to any transfer agent
for the securities of the Company held by them in order to implement the
restrictions on Transfer set forth in this Section 3.10.

          (c)  Removal of Legends, Etc. If at any time securities of the Company
cease to be subject to this Agreement, the Company will, upon the written
request of the holder of any securities bearing the first legend set forth in
Section 3.10(a), remove such legend from the certificates representing those
securities. If any Stockholder provides the Company with an opinion of counsel
(which counsel and opinion must be reasonably acceptable to the Company) or
other evidence reasonably satisfactory to the Company that any securities of the
Company held by that Stockholder have ceased to be "restricted securities"
within the meaning of the Securities Act, the Company will remove the second
legend set forth in Section 3.10(a) from the certificates representing those
securities.

     2.11 Effectiveness of Transfers. Any Common Stock Equivalents transferred
by a Stockholder (other than pursuant to an effective registration statement
under the Securities Act or a Rule 144 Transaction if the Common Stock
Equivalents are listed or admitted to trading on an Active Trading Market) shall
be held by the transferee thereof pursuant to this Agreement. Such transferee
shall, except as otherwise expressly stated herein, have all the rights and be
subject to all of the obligations of a

                                       19

<PAGE>

Stockholder under this Agreement automatically and without requiring any further
act by such transferee or by any parties to this Agreement. Without affecting
the preceding sentence, if such transferee is not a Stockholder on the date of
such Transfer, then such transferee, as a condition to such Transfer, shall
confirm such transferee's obligations hereunder in accordance with Section 3.12
hereof. No Common Stock Equivalents shall be transferred on the Company's books
and records, and no Transfer thereof shall be otherwise effective, unless any
such Transfer is made in accordance with the terms and conditions of this
Agreement, and the Company is hereby authorized by all of the Stockholders to
enter appropriate stop transfer notations on its transfer records to give effect
to this Agreement.

     2.12 Additional Stockholders; Joinder Agreement. Any Person that is not
already a party to this Agreement in the same Stockholder capacity as such
Person would be following a Transfer and who is acquiring any Common Stock
Equivalents (except for any acquisition thereof (a) in an offering registered
under the Securities Act or (b) in a Rule 144 Transaction if the Common Stock
Equivalents are listed or admitted to trading on an Active Trading Market) shall
on or before the Transfer to it of such Common Stock Equivalents, sign and
deliver to the Company a Joinder Agreement and shall thereby become a party to
this Agreement. If such Person meets the definition of a JWC Holder, then such
Person shall be treated as a JWC Holder hereunder, if such Person meets the
definition of a Halifax Holder, such Person shall be treated as a Halifax Holder
hereunder, if such Person meets the definition of a Management Holder, such
Person shall be treated as a Management Holder hereunder, and if such Person
meets none of the foregoing definitions, such Person shall be treated as an
Additional Holder hereunder. The Company shall require each Person acquiring an
option, warrant or other right to purchase shares of Common Stock under any
option or other equity participation plan to execute a Joinder Agreement.

     2.13 Prior Notice of Transfer Required. Each Stockholder agrees, prior to
any Transfer of any Common Stock Equivalents (except for any Transfer (a) in an
offering registered under the Securities Act or (b) in a Rule 144 Transaction if
the Common Stock Equivalents are listed or admitted to trading on an Active
Trading Market), to give written notice to the Company of such holder's intent
to effect such Transfer and agrees to comply in all other respects with the
provisions of this Agreement. Each such notice shall describe the manner and
circumstances of the proposed Transfer and, unless the proposed Transfer is a
Permitted Transfer or unless waived by the Company, shall be accompanied by the
written opinion, addressed to the Company, of counsel for the holder of such
Common Stock Equivalents (which counsel shall be reasonably satisfactory to the
Company), stating that in the opinion of such counsel (which opinion shall be
reasonably satisfactory to the Company) such proposed Transfer does not involve
a transaction requiring registration or qualification under the Securities Act
or the securities laws of any state of the United States or of any foreign
jurisdiction.

                                       20

<PAGE>

                                   ARTICLE III

                                Liquidity Events
                                ----------------

     3.1  General. For purposes of this Article IV, (a) the terms "register",
"registered" and "registration" refer to a registration effected by preparing
and filing a registration statement on Form S-1, S-2 or S-3 in compliance with
the Securities Act and the declaration or ordering of effectiveness of such
registration statement and (b) the term "Holder" means any Stockholder electing
to register the Transfer of any Registrable Securities pursuant to Section 4.5.

     3.2  Sale of the Company.

          (a)  From and after the fifth (5/th/) anniversary of the Purchase
Agreement Closing Date, the Majority JWC III Holders and/or the Majority Halifax
Holders, as the case may be (each, a "Selling Holder"), shall have the right
(the "Demand Sale Right") to cause the Company to consummate a transaction
constituting a Sale of the Company, which Demand Sale Right shall be exercisable
during the 30-day period commencing on each such anniversary by giving written
notice (the "Demand Sale Notice") to the Representative of the other party (the
"Non-Exercising Holder").

          (b)  As soon as practicable, the Selling Holder and the Non-Exercising
Holder shall cooperate in good faith to mutually agree upon whether or not the
consummation of the proposed Sale of the Company would result in the receipt by
the Non-Exercising Holder of an IRR (the "Anticipated IRR") of at least 25%. If,
within 30 days after the date the Demand Sale Notice was given (the "Initial
Valuation Period"), the Selling Holder and the Non-Exercising Holder are unable
to mutually agree upon whether or not the Anticipated IRR would equal at least
25%, they shall jointly select one Independent Financial Expert to establish the
Company valuation based on a per share price for the Common Stock Equivalents
equal to the Fair Market Value (as defined in clause (c) below); provided,
however, that in the event that the Selling Holder and the Non-Exercising Holder
are unable to agree upon the selection of one Independent Financial Expert
within 5 days following the Initial Valuation Period, each of the Selling Holder
and the Non-Exercising Holder shall have the right to eliminate two of the firms
listed on Exhibit C attached hereto until there is only one remaining firm on
Exhibit C, which shall be the Independent Financial Expert for purposes of
establishing such Company valuation. The Independent Financial Expert shall
deliver to each of the Selling Holder and the Non-Exercising Holder a written
opinion of its determination of the Company valuation within 20 days following
the Initial Valuation Period, or such other time as the Selling Holder and the
Non-Exercising Holder may mutually agree. The written opinion of the Independent
Financial Expert shall be conclusive and binding upon the parties. The fees of
the Independent Financial Expert shall be borne by the Company. For purposes of
this Agreement, the "Final Company Valuation" shall be either (i) the Company
valuation mutually agreed upon by the Selling Holder and the Non-Exercising
Holder or (ii) if the Selling Holder and the Non-Exercising Holder are unable to
mutually agree upon the Company valuation, the Company valuation set forth in
the written opinion delivered by the Independent Financial Expert pursuant to
this clause (b), and the "Final Valuation Date" shall be either

                                       21

<PAGE>

(A) the date on which the Selling Holder and the Non-Exercising Holder mutually
agree upon the Company valuation or (B) in the event that the Selling Holder and
the Non-Exercising Holder are unable to agree upon the Company valuation, the
date on which the Independent Financial Expert delivers its written opinion
pursuant to this clause (b).

          (c)  "Fair Market Value" as of any date shall mean, in respect of any
share of Common Stock Equivalents, the fair saleable value of such share of
Common Stock Equivalents (determined without giving effect to any discount for
(i) minority interest or (ii) lack of liquidity of the Common Stock Equivalents
or the fact that the Company may have no class of equity registered under the
Exchange Act) as of such date, as if the Company were being sold as a going
concern. For purposes of determining the value of the Company, the Independent
Financial Expert shall assume that the Company had received all consideration
payable upon exercise or conversion of all Common Stock Equivalents that were
deemed to have been exercised for purposes of computing the Common Stock
Equivalents as of the relevant date.

          (d)  Subject to Section 4.3(a), if the Selling Holder and the
Non-Exercising Holder mutually agree that, or, if they are unable to mutually
agree, based upon the Final Company Valuation as established in accordance with
clause (b)(ii) above, the Non-Exercising Holder would receive an IRR of less
than 25% as a result of the consummation of the proposed Sale of the Company,
then, unless the Selling Holder and the Non-Exercising Holder agree otherwise,
the Selling Holder shall have no further right to cause the Company to pursue,
and the Company shall not pursue, the consummation of such proposed Sale of the
Company.

          (e)  Subject to 4.3, if the Selling Holder and the Non-Exercising
Holder mutually agree that, or, if they are unable to mutually agree, based upon
the Final Company Valuation as established in accordance with clause (b)(ii)
above, the Non-Exercising Holder would receive an IRR of 25% or more as a result
of the consummation of the proposed Sale of the Company (or if the Anticipated
IRR would be less than 25% but the Selling Holder and the Non-Exercising Holder
agree, pursuant to clause (d) above, that the Selling Holder may proceed with
the proposed Sale of the Company), then the Selling Holder shall have the right
to consummate, and to cause the Company to consummate, the proposed Sale of the
Company by delivering a copy of the Demand Sale Notice to the Company and the
other Stockholders within 10 Business Days following the Final Valuation Date
(the "Selling Holder Election Date"); provided, however, that the Selling Holder
shall use commercially reasonable best efforts to complete such Sale of the
Company as soon as reasonably practicable; provided, further, that the Company
shall be entitled to rely exclusively on the delivery of any such Demand Sale
Notice without independent verification as to its validity. Subject to Section
4.3, if the Selling Holder delivers such notice, the other Stockholders will
consent to and raise no objections to the proposed Sale of the Company, and the
Stockholders and the Company will take all other actions reasonably necessary or
desirable to cause the consummation of such Sale of the Company on the terms
proposed by the Selling Holder. Without limiting the foregoing, (i) if the
proposed Sale of the Company is structured as a merger or consolidation, each
Stockholder will waive any appraisal rights which such Stockholder may have in
connection therewith and (ii) if the proposed Sale of the Company is structured
as or involves a sale or redemption of Common Stock Equivalents, each

                                       22

<PAGE>

Stockholder will (A) agree to sell its pro rata portion of the Common Stock
Equivalents being sold in such Sale of the Company on the terms and conditions
approved by the Selling Holder and (B) deliver certificates and/or other
instruments representing the pro rata portion of such Stockholder's Common Stock
Equivalents being sold, together with stock or other appropriate powers
therefore duly executed, at the closing, free and clear of all Liens (other than
pursuant to securities laws, this Agreement or a Stock Option Agreement). In
addition, each Stockholder shall (y) execute and deliver all such agreements,
instruments and certificates as the Selling Holder shall execute and deliver and
(z) upon the closing of the Sale of the Company, receive the same consideration
per Common Stock Equivalent as shall be payable to the Selling Holder (in the
case of options, warrants or similar Common Stock Equivalents, subject to
subtraction of the exercise price).

          (f)  Each Stockholder shall be severally obligated to join on a pro
rata basis (based on such Stockholder's pro rata portion of the net proceeds
paid by the Independent Third Party) in an indemnification that is to be
provided in connection with such Sale of the Company; provided that no
Stockholder shall be obligated in connection with such Sale of the Company to
agree to indemnify or hold harmless the Independent Third Party with respect to
an amount in excess of the net cash proceeds paid to such Stockholder in
connection with such Sale of the Company. All Stockholders will bear their pro
rata portion of the costs and expenses incurred in connection with such Sale of
the Company to the extent such costs are incurred for the benefit of all
Stockholders and are not otherwise paid by the Company or the Independent Third
Party.

          (g)  Each Stockholder agrees that, in such Stockholder's capacity as a
stockholder of the Company, such Stockholder shall vote, or grant proxies
relating to the Common Stock at the time held by such Stockholder to vote, all
of such Stockholder's Common Stock in favor of any such Sale of the Company
pursuant to Section 4.2(a) hereof, if, and to the extent that, approval of the
Company's stockholders is required in order to effect such Sale of the Company.

          (h)  The provisions of this Section 4.2 shall terminate and be of no
further force and effect on the earliest to occur of (i) the Selling Holder
Election Date, subject to the right of the Selling Holder to consummate the
proposed Sale of the Company in accordance with Sections 4.2 and 4.3 hereof,
(ii) the consummation of a Public Offering, and (iii) as to the Majority JWC III
Holders and the Majority Halifax Holders (as applicable), the date when such
group beneficially owns less than five percent (5%) of the Common Stock
Equivalents as of such date.

     3.3  Limitations on Demand Sale Right. Notwithstanding anything to the
contrary contained in Section 4.2 above, the Non-Exercising Holder shall have
the right (the "Blocking Right") to prevent the consummation of a proposed Sale
of the Company pursuant to Section 4.2 as follows:

          (a)  If, following the Selling Holder Election Date and based upon the
per share sale price to be paid by the Independent Third Party acquiror, the
Non-Exercising Holder would not receive an IRR of at least 25% as a result of
the consummation of the proposed Sale of the Company, the Non-

                                       23

<PAGE>

Exercising Holder may exercise its Blocking Right by giving written notice
(each, a "Blocking Notice") to the Selling Holder and the Company, which
Blocking Notice shall include a reasonably detailed calculation showing the IRR
that such Non-Exercising Holder would receive based upon the per share price to
be paid in the proposed Sale of the Company. Following receipt of such Blocking
Notice, the Selling Holder shall have no further right to cause the Company to
pursue, and the Company shall promptly cease to pursue, the consummation of,
such proposed Sale of the Company; provided, however, that the right set forth
in Section 4.2(d) and the Blocking Right set forth in this Section 4.3(a) shall
terminate on the earlier to occur of (i) the 31st day following the sixth (6th)
anniversary of the Purchase Agreement Closing Date and (ii) as to the Majority
JWC III Holders and the Majority Halifax Holders (as applicable), the date when
such group beneficially owns less than five percent (5%) of the Common Stock
Equivalents as of such date.

          (b)  In addition to the foregoing, following the Selling Holder
Election Date, the Non-Exercising Holder shall have the right (the "Blocking
Right of First Refusal") to purchase all, but not less than all, of the Common
Stock Equivalents (the "Offered Blocking Securities") then held by the Selling
Holder at the per share price for such Common Stock Equivalents established in
the Final Company Valuation (or, following the termination of the Blocking Right
pursuant to clause (a) above, the per share price equal to the Fair Market Value
of such Common Stock Equivalents, determined in accordance with the procedure
set forth in Section 4.2(b) above) by delivering a Blocking Notice to the
Selling Holder and the Company within 10 days following the Selling Holder
Election Date, which Blocking Notice shall include an express statement of its
election to exercise its Blocking Right of First Refusal hereunder. In the event
that a Blocking Right of First Refusal is exercised in accordance with this
Section 4.3, the closing of the purchase of such Offered Blocking Securities by
the Non-Exercising Holder shall take place at the principal offices of the
Company within 60 days of the date of the Blocking Notice. Notwithstanding
Section 4.12 below, the Non-Exercising Holder shall have the right, in its sole
discretion, to assign its Blocking Right of First Refusal to the Company. The
Blocking Right of First Refusal shall terminate and be of no further force and
effect as to the Majority JWC III Holders and the Majority Halifax Holders (as
applicable) on the date when such group beneficially owns less than five percent
(5%) of the Common Stock Equivalents as of such date.

          (c)  In the event that the Non-Exercising Holder does not exercise its
Blocking Right by giving a Blocking Notice within the time periods set forth in
this Section 4.3, or if the closing of the purchase of the Offered Blocking
Securities pursuant to the Blocking Right of First Refusal does not occur within
the period set forth in clause (b) above, the Selling Holder may cause the
Company to consummate the proposed Sale of the Company on the terms proposed by
the Selling Holder.

                                       24

<PAGE>

     3.4  Demand Registration. Subject to Section 4.4(e), if the Company shall
be requested, in writing at any time and from time to time, by the Majority JWC
Equity Partners Holders, the Majority JWC III Holders and/or the Majority
Halifax Holders, as the case may be (each, a "Requesting Holder"), to effect a
registration statement under the Securities Act of Registrable Securities, the
Company shall promptly (a) give written notice of the proposed registration to
all other Stockholders that then hold Registrable Securities and (b) use its
best efforts to effect the registration under the Securities Act of the public
offer and sale of the Registrable Securities which the Company has been so
requested to register by the Requesting Holder and by other Stockholders that
then hold Registrable Securities in a written request received by the Company
within 10 Business Days after the giving of the written notice specified in
clause (a) above; provided, however, that the Company shall not be obligated to
effect any registration under the Securities Act , following the Company's
initial Public Offering, at anytime and from time to time, except in accordance
with the following provisions:

          (a)  The Company shall not be obligated to use its best efforts to
file and cause to become effective any registration statement during any period
in which any other registration statement (other than on Forms S-4, F-4 or S-8
promulgated under the Securities Act or any successor forms thereto) pursuant to
which Primary Shares are to be or were sold has been filed and not withdrawn or
has been declared effective within the prior 90 days.

          (b)  The Company may delay the filing or effectiveness of any
registration statement requested pursuant to this Section 4.4 for a period of up
to 90 days after the date of a request for registration pursuant to this Section
4.4 if at the time of such request (i) the Company is engaged, or has fixed
plans to engage within 90 days after the date of such request, in a firm
commitment underwritten public offering of Primary Shares in which the holders
of Registrable Securities may include Registrable Securities pursuant to Section
4.5 or (ii) a Material Transaction exists, provided that the Company may only so
delay the filing or effectiveness of any registration statement once per twelve
month period pursuant to this Section 4.4(b).

          (c)  With respect to any registration pursuant to this Section 4.4,
the Company may include in such registration any Primary Shares; provided,
however, that, if the managing underwriter advises the Company that the
inclusion of all Registrable Securities and Primary Shares proposed to be
included in such registration would interfere with the successful marketing
(including pricing) of the Registrable Securities proposed to be included in
such registration, then the number of Registrable Securities and Primary Shares
proposed to be included in such registration shall be included in the following
order:

               (i)   first, the Registrable Securities, pro rata based on the
number of Registrable Securities held by the Requesting Holder and each other
Holder seeking to have Registrable Securities included in such registration; and

               (ii)  second, the Primary Shares.

                                       25

<PAGE>

          (d)  If the method of disposition requested by the Requesting Holder
pursuant to this Section 4.4 is an underwritten public offering, the Requesting
Holder, or its Representative, shall have the right to designate the managing
underwriter of such offering, subject to the consent of the Company, which
consent shall not be unreasonably withheld. If any Holder disapproves of the
terms of any such underwriting, it may elect to withdraw therefrom by written
notice to the Company and the underwriter prior to the date of pricing such
Public Offering. Any Registrable Securities or other securities excluded or
withdrawn from such underwriting shall be withdrawn from such registration.

          (e)  In the event that a Demand Registration pursuant to this Section
4.4 is requested by the Majority Halifax Holders (the "Halifax Demand
Registration"), the following shall apply:

               (i)   the Company is obligated to effect only one (1) Halifax
Demand Registration; provided, however, that any registration requested by the
Majority Halifax Holders pursuant to this Section 4.4 that does not become
effective shall not count as the one (1) Halifax Demand Registration for
purposes of this Section 4.4(e);

               (ii)  the Company is obligated to effect the Halifax Demand
Registration only after the Company's initial Public Offering; and

               (iii) the Majority Halifax Holders shall not be entitled to
request the Company to effect, and the Company shall not effect, the Halifax
Demand Registration until all Registrable Securities covered by the first Demand
Registration requested by the Majority JWC Equity Partners Holders and/or the
Majority JWC III Holders (as the case may be) shall have been disposed of.

          (f)  A Requesting Holder may, at any time prior to the effective time
of a registration statement filed hereunder, revoke such request by providing a
written notice to the Company revoking such request.

          (g)  The right to request registrations pursuant to this Section 4.4
shall terminate and be of no further force and effect (i) with respect to the
Existing JWC Investors, on the date when the Existing JWC Investors beneficially
own less than five percent (5%) of the Common Stock Equivalents as of the
relevant date; (ii) with respect to the JWC Investors, on the date when the JWC
Investors beneficially own less than five percent (5%) of the Common Stock
Equivalents as of the relevant date and (iii) with respect to the Halifax
Holders, on the date when the Halifax Holders beneficially own less than five
percent (5%) of the Common Stock Equivalents as of the relevant date.

                                       26

<PAGE>

     3.5  Piggyback Registration.

          (a)  If, at any time, the Company determines to register the public
offer and sale of any Common Stock under the Securities Act (other than pursuant
to Section 4.4), the Company shall, at each such time, promptly give each
Stockholder that then holds Registrable Securities written notice of such
determination no later than 30 days before its intended filing with the SEC.
Upon the written request of any Stockholder that then holds Registrable
Securities received by the Company within 10 Business Days after the giving of
any such notice by the Company, the Company shall use its best efforts to effect
the registration under the Securities Act of the public offer and sale of all of
the Registrable Securities of such Stockholder that such Holder has requested be
registered for disposition in accordance with the intended method of disposition
as stated in such notice by the Company and with the underwriter selected by the
Company.

          (b)  If the managing underwriter advises the Company that the
inclusion of all Registrable Securities and Primary Shares proposed to be
included in such registration would interfere with the successful marketing
(including pricing) of the securities proposed to be included in such
registration, then the number of Registrable Securities and Primary Shares
proposed to be included in such registration shall be included in the following
order:

                    first, all Primary Shares offered for the account of the
                    Company; and

                    second, the Registrable Securities, pro rata based on the
                    number of Registrable Securities held by each Holder seeking
                    to have Registrable Securities included in such
                    registration.

Notwithstanding the foregoing, the Company shall not be obligated to include in
an initial Public Offering any Registrable Securities of any Holder if the JWC
Holders do not elect to include their Registrable Securities in such a
registration. If any Holder disapproves of the terms of any such underwriting,
it may elect to withdraw therefrom by written notice to the Company and the
underwriter prior to the date of pricing such Public Offering. Any Registrable
Securities or other securities excluded or withdrawn from such underwriting
shall be withdrawn from such registration.

     3.6  Obligations of the Company.

          (a)  Whenever required under Section 4.4 or 4.5 to use its best
efforts to effect the registration of the public offer and sale of any
Registrable Securities, the Company shall (provided, that if such registration
is being effected pursuant to Section 4.5, the Company may at any time delay or
abandon the underlying registration without any liability to the Holders):

                                       27

<PAGE>

               (i)   prepare and file with the SEC a registration statement (or
     an amendment to a registration statement) with respect to the public offer
     and sale of such Registrable Securities and use its best efforts to cause
     such registration statement to become effective.

               (ii)  as expeditiously as reasonably possible, prepare and file
     with the SEC all amendments and supplements to such registration statement
     and the prospectus contained therein as may be necessary to comply with the
     provisions of the Securities Act with respect to the disposition of all
     securities covered by such registration statement and to keep each
     registration and qualification under this Agreement current and effective
     (and in compliance with the Securities Act) by such actions as may be
     necessary or appropriate for a period of 120 days after the effective date
     of such registration statement (unless all securities covered by such
     registration statement are sooner disposed of), all as requested by such
     Holder or Holders; provided, however, that after the Company has qualified
     for the use of Form S-3, the Majority JWC Equity Partners Holders, the
     Majority JWC III Holders and/or the Majority Halifax Holders, as the case
     may be, shall have the right to request the Company to effect a
     registration on Form S-3 pursuant to Rule 415 promulgated under the
     Securities Act and to keep such registration effective until all securities
     covered thereby are disposed of.

               (iii) as expeditiously as reasonably possible furnish to the
     Holders such numbers of copies of a prospectus, including a preliminary
     prospectus, in conformity with the requirements of the Securities Act, and
     such other documents as they may reasonably request in order to facilitate
     the disposition of Registrable Securities owned by them in accordance with
     the plan of distribution provided for in such registration statement;

               (iv)  as expeditiously as reasonably possible use its best
     efforts to register and qualify the securities covered by such registration
     statement under such securities or "blue sky" laws of such jurisdictions as
     shall be reasonably appropriate for the distribution of the securities
     covered by the registration statement, provided that the Company shall not
     be required in connection therewith or as a condition thereto to register
     as a foreign corporation or to qualify to do business in any jurisdiction
     it would not otherwise be required to be so registered or qualified but for
     this subsection (iv), to file a general consent to service of process in
     any such jurisdiction, to subject itself to taxation in any such
     jurisdiction or to register as a dealer in securities in any jurisdiction,
     and further provided that (anything in this Agreement to the contrary
     notwithstanding with respect to the bearing of expenses) if any
     jurisdiction in which the securities shall be qualified shall require by
     law or regulation that expenses incurred in connection with the
     qualification of the securities in that jurisdiction be borne by selling
     stockholders, then such expenses shall be payable by selling stockholders
     pro rata, to the extent required by such jurisdiction;

               (v)   notify each Holder of Registrable Securities covered by
     such registration statement, at any time when a prospectus relating thereto
     is required to be delivered under the

                                       28

<PAGE>

     Securities Act, upon discovery that, or upon the happening of any event as
     a result of which, the prospectus included in such registration statement,
     as then in effect, includes an untrue statement of a material fact or omits
     to state any material fact required to be stated therein or necessary to
     make the statements therein not misleading in the light of the
     circumstances under which they were made (provided that upon such
     notification, each Holder agrees not to sell or otherwise transfer or
     dispose of any Common Stock (or other securities) of the Company at the
     time held by such Holder or any interest or future interest therein until
     such statement or omission has been corrected, and there shall be added to
     the period during which the Company is obligated to keep such registration
     effective the number of days for which such sales or other transfers or
     dispositions were suspended), and at the request of any such Holder
     promptly prepare and furnish, without charge, to such seller or Holder a
     reasonable number of copies of a supplement to such prospectus or an
     amendment of such registration statement as may be necessary so that, as
     thereafter delivered to the purchasers of such securities, such prospectus
     shall not include an untrue statement of a material fact or omit to state a
     material fact required to be stated therein or necessary to make the
     statements therein not misleading in the light of the circumstances under
     which they were made;

               (vi)  otherwise use its best efforts to comply with all
     applicable rules and regulations of the SEC, and make available to its
     security holders, as soon as reasonably practicable, an earnings statement
     covering the period of at least 12 months but not more than 18 months,
     beginning with the first full calendar month after the effective date of
     such registration statement, which earnings statement shall satisfy the
     provisions of Section 11(a) of the Securities Act or Rule 158 thereunder;
     and

               (vii) use its best efforts to list all Registrable Securities
     covered by such registration statement on any securities exchange on which
     any class of similar Securities is then listed.

          (b)  If the Company at any time proposes to register the public offer
and sale of any of its securities under the Securities Act in a registration
that is subject to the registration rights of the Holders under Section 4.4 or
4.5, and such securities are to be distributed by or through one or more
underwriters selected by the Company, then the Company will, subject to Section
4.5(b) above, use its best efforts, if requested by any Holder of Registrable
Securities who requests such registration, to arrange for such underwriters to
include such Registrable Securities among the securities to be distributed by or
through such underwriters.

          (c)  In connection with the preparation and filing of each
registration statement registering the public offer and sale of Registrable
Securities under this Agreement, the Company will give the Holders of
Registrable Securities on whose behalf the public offer and sale of such
Registrable Securities are to be so registered and their underwriters, if any,
and their respective counsel and accountants the opportunity to participate in
the preparation of such registration statement, each prospectus included therein
or filed with the SEC, and each amendment thereof or supplement thereto, and
will give

                                       29

<PAGE>

each of them such access to its books and records and such opportunities to
discuss the business of the Company with its officers, its counsel and the
independent public accountants who have certified its financial statements, as
shall be reasonably necessary, in the opinion of such Holders or such
underwriters or their respective counsel, in order to conduct a reasonable and
diligent investigation within the meaning of the Securities Act.

     3.7  Furnish Information. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Article IV that
each Holder shall furnish to the Company such information regarding such Holder,
the Registrable Securities held by such Holder, and the intended method of
disposition of such securities as the Company shall reasonably request and as
shall be required in connection with the action to be taken by the Company.

     3.8  Expenses of Registration. Registration, filing and qualification fees,
printers' and accounting fees, fees and expenses of compliance with securities
or blue sky laws, fees and expenses relating to filings with the National
Association of Securities Dealers, Inc. or any applicable securities exchange,
fees of underwriters (excluding discounts, commissions or fees of underwriters,
selling brokers, dealer managers or similar securities industry professionals
attributable to the Registrable Securities being registered), and fees and
disbursements of counsel for the Company incurred in connection with a
registration pursuant to Section 4.4 or 4.5 shall be borne by the Company. Each
Holder whose shares are being sold will bear, pro rata, underwriters' discounts
and brokerage and other commissions, fees and disbursements of its own counsel
and all of its other expenses of such registration, offering and sale.

     3.9  Underwriting Requirements. In connection with any registration of
Registrable Securities under this Agreement, the Holders whose shares are being
sold shall, if requested by the Company or the underwriters, enter into an
underwriting agreement with such underwriters for such offering, such agreement
to contain such terms and provisions as are customarily contained in
underwriting agreements with respect to secondary distributions, including,
without limitation, provisions relating to indemnification and contribution. The
Holders on whose behalf Registrable Securities are to be distributed shall also
complete and execute all questionnaires, powers of attorney and/or other
documents required under the terms of such underwriting agreement.

     3.10 Indemnification. In the event any Registrable Securities are included
in a registration statement pursuant to this Article IV:

          (a)  To the fullest extent permitted by law, the Company will
indemnify and hold harmless each Holder joining in a registration and its
directors and officers, any underwriter (as defined in the Securities Act) for
it, and each Person, if any, who controls such Holder or such underwriter within
the meaning of the Securities Act, from and against any losses, claims, damages,
expenses (including reasonable attorneys' fees and expenses and reasonable costs
of investigation) or liabilities, joint or several, to which they or any of them
may become subject under the Securities Act or otherwise, insofar as such
losses, claims, damages, expenses or liabilities (or actions or proceedings,
whether commenced or

                                       30

<PAGE>

threatened, in respect thereof) arise out of or are based on any untrue or
alleged untrue statement of any material fact contained in such registration
statement including any preliminary prospectus or final prospectus contained
therein or any amendments or supplements thereto, or arise out of or are based
upon the omission or alleged omission to state therein a material fact required
to be stated therein or necessary to make the statements made therein not
misleading in light of the circumstances under which they were made, provided
that the indemnity agreement contained in this Section 4.10(a) shall not apply
to amounts paid in settlement of any such loss, claim, damage, liability or
action if such settlement is effected without the consent of the Company (which
consent shall not be unreasonably withheld), nor shall the Company be liable for
any such loss, claim, damage, liability or action to the extent that it arises
out of or is based upon (i) an untrue statement or omission made in connection
with such registration statement, preliminary prospectus, final prospectus or
amendments or supplements thereto in reliance upon and in conformity with
written information furnished by such Holder, underwriter or control person to
the Company specifically for inclusion in the Registration Statement in
connection with such registration, or (ii) such Holder's failure to deliver a
copy of the registration statement or prospectus or any amendments or
supplements thereto after the Company has furnished such Holder with a
sufficient number of copies of the same. Such indemnity shall remain in full
force and effect regardless of any investigation made by or on behalf of such
Holder, underwriter or control person and shall survive the transfer of such
securities by such Holder.

          (b)  To the fullest extent permitted by law, each Holder joining in a
registration shall indemnify and hold harmless the Company, each of its
directors, each of its officers who has signed the registration statement, each
Person, if any, who controls the Company within the meaning of the Securities
Act, and each agent and any underwriter for the Company and any Person who
controls any such agent or underwriter and each other Holder and any Person who
controls such Holder (within the meaning of the Securities Act) against any
losses, claims, damages, expenses (including reasonable attorney's fees and
expenses and reasonable costs of investigation) or liabilities to which the
Company or any such director, officer, control person, agent, underwriter or
other Holder may become subject, under the Securities Act or otherwise, insofar
as such losses, claims, damages or liabilities (or actions or proceedings,
whether commenced or threatened, in respect thereof) arise out of or are based
upon an untrue statement of any material fact contained in such registration
statement, including any preliminary prospectus or final prospectus contained
therein or any amendments or supplements thereto, or arise out of or are based
upon (i) the omission to state therein a material fact required to be stated
therein or necessary to make the statements therein not misleading, in each case
to the extent that such untrue statement or omission was made in such
registration statement, preliminary or final prospectus, or amendments or
supplements thereto, in reliance upon and in conformity with written information
furnished by such Holder in connection with such registration specifically for
inclusion in the Registration Statement in connection with such registration, or
(ii) such Holder's failure to deliver a copy of the registration statement or
prospectus or any amendments or supplements thereto after the Company has
furnished such Holder with a sufficient number of copies of the same, provided
that the indemnity agreement contained in this Section 4.10(b) shall not apply
to amounts paid in settlements effected without the consent of such Holder
(which consent shall not be unreasonably withheld). Such indemnity shall remain
in full force and effect regardless of any investigation

                                       31

<PAGE>

made by or on behalf of the Company or any such director, officer, Holder,
underwriter or control person and shall survive the transfer of such securities
by such Holder.

          (c)  Any Person seeking indemnification under this Section 4.10 will
(i) give prompt written notice to the indemnifying party of any claim with
respect to which it seeks indemnification, but the failure to give such notice
will not affect the right to indemnification hereunder, except to the extent the
indemnifying party is actually prejudiced by such failure and (ii) unless in
such indemnified party's reasonable judgment a conflict of interest may exist
between such indemnified and indemnifying parties with respect to such claim,
permit such indemnifying party, and other indemnifying parties similarly
situated, jointly to assume the defense of such claim with counsel reasonably
satisfactory to the parties. In the event that the indemnifying parties cannot
mutually agree as to the selection of counsel, each indemnifying party may
retain separate counsel to act on its behalf and at its own expense. The
indemnified party shall in all events be entitled to participate in such defense
at its expense through its own counsel. If such defense is not assumed by the
indemnifying party, the indemnifying party will not be subject to any liability
for any settlement made without its consent (but such consent will not be
unreasonably withheld). No indemnifying party will consent to entry of any
judgment or enter into any settlement which does not include as an unconditional
term thereof the giving by the claimant or plaintiff to such indemnified party
of a release from all liability in respect of such claim or litigation. An
indemnifying party who is not entitled to, or elects not to, assume the defense
of a claim will not be obligated to pay (or contribute to the payment of) the
fees and expenses of more than one counsel for all parties indemnified by such
indemnifying party with respect to such claim.

          (d)  If for any reason the foregoing indemnification is unavailable to
any party or insufficient to hold it harmless as and to the extent contemplated
by the preceding paragraphs of this Section 4.10, then each indemnifying party
shall contribute to the amount paid or payable by the indemnified party as a
result of such loss, claim, damage expense or liability in such proportion as is
appropriate to reflect the relative benefits received by the indemnifying party,
on the one hand, and the applicable indemnified party, as the case may be, on
the other hand, and also the relative fault of the indemnifying party and any
applicable indemnified party, as the case may be, as well as any other relevant
equitable considerations. No person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) shall be entitled to
contribution from any person or entity who was not guilty of such fraudulent
misrepresentation.

     3.11 Market Stand-Off Agreement. If requested by the managing underwriter
of the initial Public Offering on behalf of the Company of its Common Stock, or
by the managing underwriter of any Public Offering for which the public offer
and sale of Registrable Securities of any Holders have been registered, no
Holder shall sell or otherwise transfer or dispose of any Registrable Securities
held by such Holders (other than pursuant to Permitted Transfers, pursuant to
Sections 3.3, 3.4 or 4.2 and other than those Registrable Securities included in
the registration) during such period following the effective date of such
registration as is usual and customary, in the reasonable opinion of such
managing underwriter, at such time in similar public offerings of similar
securities.

                                       32

<PAGE>

     3.12 Rights Non-Transferable. Notwithstanding anything to the contrary
herein, the rights set forth in Sections 4.2, 4.3 and 4.4 of (a) the Majority
JWC III Holders and their Permitted Transferees (other than JWC Equity Partners,
Halifax Holders and Management Holders) may only be exercised by the Majority
JWC III Holders and their Permitted Transferees (other than JWC Equity Partners,
Halifax Holders and Management Holders), and may not be transferred or assigned
in connection with any other Transfer of Common Stock Equivalents or otherwise,
(b) the Majority JWC Equity Partners Holders and their Permitted Transferees
(other than JWC Equity Partners III, Halifax Holders and Management Holders) may
only be exercised by the Majority JWC Equity Partners Holders and their
Permitted Transferees (other than JWC Equity Partners III, Halifax Holders and
Management Holders), and may not be transferred or assigned in connection with
any other Transfer of Common Stock Equivalents or otherwise and (c) the Majority
Halifax Holders and their Permitted Transferees (other than JWC Equity Partners,
JWC Equity Partners III and Management Holders) may only be exercised by the
Majority Halifax Holders and their Permitted Transferees (other than JWC Equity
Partners, JWC Equity Partners III and Management Holders) and may not be
transferred or assigned in connection with any other Transfer of Common Stock
Equivalents or otherwise.

                                   ARTICLE IV

                              Corporate Governance
                              --------------------

     5.1  Board of Directors.

          (a)  The Company and each of the Stockholders shall take all action,
including, but not limited to, such Stockholder's voting, or executing proxies
or written consents with respect to, the Voting Stock at the time held by such
Stockholder as may be from time to time requested either by the holders of a
majority of the Common Stock Equivalents at the time held by the JWC Holders or
by the JWC Representative so that the Board of Directors shall consist of such
number of directors as may be from time to time designated either by the holders
of a majority of the Common Stock Equivalents at the time held by the JWC
Holders or by the JWC Representative.

          (b)  The Company and each of the Stockholders shall take all action,
including, but not limited to, such Stockholder's voting, or executing proxies
or written consents with respect to, the Voting Stock at the time held by such
Stockholder as may be from time to time requested either by holders of a
majority of the Common Stock Equivalents at the time held by the JWC Holders or
by the JWC Representative so that the Board of Directors shall include such
directors as may be from time to time designated either by the holders of a
majority of the Common Stock Equivalents at the time held by the JWC Holders or
by the JWC Representative, including directors constituting a majority of the
Board of Directors. Either the holders of a majority of the Common Stock
Equivalents at the time held by the JWC Holders or the JWC Representative shall
also be entitled to require that any member of the Board of Directors so
designated pursuant to this Section 5.1(b) be removed or replaced by another
designee of

                                       33

<PAGE>

either the holders of a majority of the Common Stock Equivalents at the time
held by the JWC Holders or the JWC Representative, in which event the Company
and each Stockholder shall take all action, including, but not limited to, such
Stockholder's voting, or executing proxies or written consents with respect to,
the Voting Stock at the time held by such Stockholder as may be necessary to
effect such removal or replacement.

          (c)  Notwithstanding the provisions of Section 5.1(b), the Company and
each Stockholder shall take all action, including, but not limited to, such
Stockholder's voting, or executing proxies or written consents with respect to,
the Voting Stock at the time held by such Stockholder as may be from time to
time requested either by the holders of a majority of the Common Stock
Equivalents at the time held by the Halifax Holders or by the Halifax
Representative, so that the Board of Directors shall include two directors
designated either by the holders of a majority of the Common Stock Equivalents
held by the Halifax Holders or by the Halifax Representative which directors
(the "Halifax Directors") shall initially be David W. Dupree and Brent D.
Williams; provided, that the number of Halifax Directors that the Halifax
Holders or the Halifax Representative shall be entitled to designate pursuant to
this Section 5.1(c) shall be permanently reduced from 2 to 1 director at such
time as the Halifax Holders hold less than 50% of the Common Stock Equivalents
held by the Original Halifax Holders as of the date of this Agreement; provided,
further, that the number of Halifax Directors designated pursuant to this
Section 5.1(c) shall be permanently reduced to zero directors at such time as
the Halifax Holders hold less than 5% of the Common Stock Equivalents
outstanding. Either the holders of a majority of the Common Stock Equivalents at
the time held by the Halifax Holders or the Halifax Representative shall also be
entitled to require that any Halifax Director be removed or replaced by another
designee of the holders of either the majority of the Common Stock Equivalents
at the time held by the Halifax Holders or of the Halifax Representative, in
which event the Company and each Stockholder shall take all action, including,
but not limited to, such Stockholder's voting, or executing proxies or written
consents with respect to, the Voting Stock at the time held by such Stockholder
as may be necessary to effect such removal or replacement.

     4.1  Rights of the Halifax Directors and Halifax.

          (a)  Notwithstanding that no vote may be required, or that a lesser
percentage vote may be specified in the certificate of incorporation or by-laws
of the Company, the Company shall not take, and no Stockholder shall cause the
Company to take, any of the following actions without the affirmative vote (the
"Halifax Affirmative Vote") of (y) a majority of the Board of Directors, which
majority vote shall include the affirmative vote of the Halifax Directors, if
any, and (z) the Majority Halifax Holders:

               (i)   the redemption, purchase or other acquisition of any Common
Stock Equivalents other than those redemptions, purchases or acquisitions made
(a) pursuant to this Agreement, (b) on a pro rata basis among the holders of a
particular class or series of securities of the Company, (c) pursuant to the
terms of securities of the Company created after the date hereof which require
such redemption, purchase or acquisition (including the terms of any stock
option agreement) or (d) in accordance with the Repurchases, as defined in the
Purchase Agreement;

                                       34

<PAGE>

               (ii)  the declaration or payment of any dividend or other
distribution by the Company with respect to any Common Stock Equivalents other
than those declarations or payments of dividends or other distributions that are
made (a) pursuant to this Agreement, (b) on pro rata basis among the holders of
a particular class or series of securities of the Company or (c) pursuant to the
terms of securities of the Company created after the date hereof which require
such declaration, payment or other distribution;

               (iii) the termination of the Chief Executive Officer of the
Company without Cause (as defined in such individual's then current employment
agreement with the Company);

               (iv)  any issuance of Common Stock Equivalents in connection with
a transaction or series of related transactions involving an acquisition of the
equity or assets of a Third Party which results in an aggregate issuance of
greater than 20% of the total outstanding Common Stock Equivalents,

               (v)   the entering into of any transaction or agreement (other
than pursuant to this Agreement), directly or indirectly, by the Company, or any
Subsidiary of the Company, with JWC Inc. or any director, officer, employee or
Affiliate of JWC Inc., including any of the portfolio companies held or managed
by any such entity (which affirmative vote of the Halifax Directors shall not be
unreasonably withheld); or

               (vi)  any significant change in the nature of the Company's
business as of the date hereof.

Notwithstanding anything to the contrary herein, (x) the Halifax Affirmative
Vote shall no longer be necessary with respect to the matters set forth in
clauses (iii) and (iv) above at such time as the Halifax Holders hold less than
50% of the Common Stock Equivalents held by the Original Halifax Holders as of
the date of this Agreement and (y) the provisions of this Section 5.2 shall
terminate at such time as the Halifax Holders hold less than 5% of the Common
Stock Equivalents.

          (b)  As long as at least one Halifax Director is a member of the Board
of Directors, there shall be at least one Halifax Director on each committee, if
any, established by the Board of Directors.

     4.2  Rights Non-Transferable. Notwithstanding anything to the contrary
herein, the rights of the Halifax Holders and the Halifax Directors under
Section 5.1 and 5.2, respectively, may only be exercised by the Halifax Holders
and Halifax Directors, respectively, and may not be transferred or assigned in
connection with any other Transfer of Common Stock Equivalents or otherwise.

                                       35

<PAGE>

                                    ARTICLE V

                                Preemptive Rights
                                -----------------

     5.1  Rights to Subscribe for Securities.

          (a)  Preemptive Offer. Except in the case of Excluded Securities (as
defined in Section 6.1(e)), the Company, or any Subsidiary of the Company, shall
not issue or sell any Common Stock Equivalent, unless the Company shall have
first offered, or caused such Subsidiary to offer (the "Preemptive Offer") to
sell such Common Stock Equivalents (the "Offered Securities") to each JWC Holder
and Halifax Holder (each, a "Preemptive Offeree") by delivery to each Preemptive
Offeree of a written notice of such Preemptive Offer stating that the Company or
such Subsidiary proposes to sell such Offered Securities, the number or amount
of the Offered Securities proposed to be sold, the proposed purchase price
therefor (or, in the case of an offering in which the price is not known at the
time notice is given, the method of determining such price and a good faith
estimate thereof) and any other terms and conditions of such offer. The
Preemptive Offer shall by its terms remain open and irrevocable for a period of
10 Business Days from the date it is received by the Preemptive Offerees (the
"Preemptive Offer Period").

          (b)  Preemptive Offer Acceptance. Each Preemptive Offeree shall have
the option, exercisable at any time during the Preemptive Offer Period by
delivering written notice to the Company or such Subsidiary (a "Preemptive Offer
Acceptance Notice"), to subscribe for the number or amount of such Offered
Securities that would permit such Preemptive Offeree to maintain its Offeree
Percentage as it existed immediately prior to such issuance, sale or exchange
(the "Preemptive Offer Allocation"), with the number of Offered Securities in
excess of such Preemptive Offer Allocation to be issued as proposed by the
Company or such Subsidiary. In the event that any Preemptive Offeree elects not
to acquire Offered Securities equal to its Preemptive Offer Allocation, such
Preemptive Offeree shall deliver to the other Preemptive Offerees (with a copy
to the Company or such Subsidiary) written notice of such election within 7
Business Days from the date of receipt of the Preemptive Offer, which notice
shall include the number of Offered Securities not elected to be purchased by
such Preemptive Offeree (the "Unpurchased Preemptive Shares"). Each of the
Preemptive Offerees electing to acquire Offered Securities equal to its
Preemptive Offer Allocation (collectively, the "Exercising Preemptive Offerees")
may elect, by written notice to the Company or such Subsidiary on or before the
expiration of the Preemptive Offer Period, to purchase all or a portion of the
Unpurchased Preemptive Shares. If the Exercising Preemptive Offerees deliver
notices electing to purchase more than the total number of Unpurchased
Preemptive Shares, the Unpurchased Preemptive Shares shall be allocated on a
pro-rata basis based on the number of Common Stock Equivalents held by such
Exercising Preemptive Offerees.

          (c)  Offer of Refused Securities. If Preemptive Offer Acceptance
Notices are not given by the Preemptive Offerees for all of the Offered
Securities, the Company or such Subsidiary shall have 60 days from the
expiration of the Preemptive Offer Period to sell all or any part of such
Offered Securities

                                       36

<PAGE>

as to which Preemptive Offer Acceptances Notices have not been given by the
Preemptive Offerees (the "Refused Securities") to any other Persons upon terms
and conditions, including price, which are no more favorable, in the aggregate,
to such other Persons or less favorable to the Company or such Subsidiary than
those set forth in the Preemptive Offer.

          (d)  Closing. The closing with respect to the purchase and sale of
Offered Securities pursuant to this Article VI shall take place at the principal
offices of the Company on the first Business Day following the expiration of the
Preemptive Offer Period, or such other time as the Company and the relevant
Preemptive Offeree(s) may agree, and at such closing, the Preemptive Offerees
that delivered timely Preemptive Offer Acceptance Notices shall purchase from
the Company or such Subsidiary, and the Company or such Subsidiary shall sell to
such Preemptive Offerees, the Offered Securities with respect to which
Preemptive Offer Acceptance Notices were delivered, on the same terms as
specified in the Preemptive Offer.

          (e)  Excluded Securities. The rights of the Preemptive Offerees under
this Section 6.1 shall not apply to the following securities (the "Excluded
Securities"):

               (i)   any Common Stock Equivalents issued or granted pursuant to
a stock option or other similar equity incentive plan providing for issuance to
employees, directors, officers or consultants of the Company or its
Subsidiaries;

               (ii)  any Common Stock Equivalents and other derivative
securities issued upon the exercise or conversion of any other Common Stock
Equivalents or other options;

               (iii) any Common Stock Equivalents issued to any Person not
affiliated with the Company, which, in connection with the issuance of Common
Stock Equivalents to such Person, simultaneously enters into a significant
business transaction (including, but not limited to, debt financings and
acquisitions of businesses or assets) with the Company which is directly related
to the Company's business;

               (iv)  any Common Stock Equivalents issued as part of a Public
Offering or pursuant to any effective registration statement under the
Securities Act;

               (v)   any Common Stock Equivalents issued to the Company or a
Subsidiary; and

               (vi)  any Common Stock issued pursuant to the Purchase Agreement,
whether on the Purchase Agreement Closing Date or thereafter.

                                       37

<PAGE>

                                   ARTICLE VI

                     Certain Miscellaneous Other Provisions
                     --------------------------------------

     6.1  Remedies. Each of the parties hereto acknowledges and agrees that no
remedy at law would be adequate in the event of any breach of this Agreement.
Accordingly, if any dispute arises concerning the sale or other disposition of
any of the securities of the Company subject to this Agreement or concerning any
other provisions hereof or the obligations of the parties hereunder, each party
hereto agrees that, in addition to any other remedy to which they may be
entitled at law or in equity, the other parties hereto shall be entitled to a
decree of specific performance to enforce this Agreement (without bond or other
security being required unless the party seeking such remedy fails to
demonstrate to an appropriate court having jurisdiction that such party has a
likelihood of success on the merits), and each party hereto waives the defense
in any action or proceeding brought to enforce this Agreement that there exists
an adequate remedy at law. Such remedies shall be cumulative and non-exclusive
and shall be in addition to any other rights and remedies the parties may have
under this Agreement or otherwise.

     6.2  Entire Agreement; Amendment; Termination.

          (a)  Subject to Section 7.16 hereof, this Agreement sets forth the
entire understanding of the parties, and supersedes all prior agreements and all
other arrangements and communications, whether oral or written, with respect to
the subject matter hereof, and, as of the date hereof, the Existing Stockholders
Agreement is amended and restated in its entirety herein.

          (b)  The Schedule of Stockholders may be amended in writing by the
Company to reflect changes in the composition of the Stockholders and changes in
their addresses or telecopy numbers that may occur from time to time as a result
of Permitted Transfers, Transfers in accordance with Articles III or IV hereof
or any new issuance by the Company of Common Stock Equivalents; provided,
however, that no new issuance of Common Stock Equivalents shall be effective
unless and until the Person receiving such securities (if not already a party
hereto in such capacity) executes and delivers to the Company an executed
Joinder Agreement in accordance with Section 3.12 hereof. Amendments to the
Schedule of Stockholders reflecting Permitted Transfers or Transfers in
accordance with Articles III or IV hereof shall become effective when the
amended Schedule of Stockholders, and a copy of a Joinder Agreement as executed
by any new transferee in accordance with Section 3.12, are filed with the
Company.

          (c)  Any other amendment to this Agreement shall be in writing and
shall require the written consent of (i) the Company, (ii) either the JWC
Representative or the holders of a majority of Common Stock Equivalents at the
time held by the JWC Holders, (iii) if adverse to the interests of any
Stockholder Group, then the consent of a majority of the Common Stock
Equivalents at the time held by such Stockholder Group and (iv) if adverse to
the interests of a particular Stockholder or Stockholders in a manner different
from its effect on other Stockholders in the same Stockholder Group, then the
consent

                                       38

<PAGE>

of such Stockholder or the holders of a majority of the Common Stock Equivalents
at the time held by those particular Stockholders (as applicable).

          (d)  Notwithstanding the foregoing provisions of this Section 7.2,
this Agreement may be terminated at any time upon the written consent of (i) the
Company and (ii) each of (A) the holders of a majority of the Common Stock
Equivalents at the time held by the Management Holders, (B) either the holders
of a majority of the Common Stock Equivalents at the time held by the Halifax
Holders or the Halifax Representative and (C) either the holders of a majority
of the Common Stock Equivalents at the time held by the JWC Holders or the JWC
Representative.

     6.3  Severability. Any term or provision of this Agreement that is invalid
or unenforceable in any situation in any jurisdiction shall not affect the
validity or enforceability of the remaining terms and provisions hereof or the
validity or enforceability of the offending term or provision in any other
situation or in any other jurisdiction. If the final judgment of a court of
competent jurisdiction declares that any term or provision hereof is invalid or
unenforceable, the parties agree that the body making the determination of
invalidity or unenforceability shall have the power to reduce the scope,
duration or area of the term or provision, to delete specific words or phrases,
or to replace any invalid or unenforceable term or provision with a term or
provision that is valid and enforceable and that comes closest to expressing the
intention of the invalid or unenforceable term or provision, and this Agreement
shall be enforceable as so modified after the expiration of the time within
which the judgment may be appealed.

     6.4  Notices. All notices, consents, waivers, and other communications
under this Agreement must be in writing and will be deemed to have been duly
given when (a) delivered by hand (with written confirmation of receipt), (b) 3
days following deposit with the U.S. mail for delivery by registered mail,
return receipt requested, or (c) the Business Day following delivery to a
nationally recognized overnight delivery service (requiring signature for
delivery), in each case to the appropriate addresses and telecopier numbers set
forth below (or to such other addresses and telecopier numbers as a party may
designate by written notice to the other parties):

          (a)  For notices and communications to the Company:

                    c/o J.W. Childs Associates, L.P.
                    111 Huntington Avenue, Suite 2900
                    Boston, MA 02199
                    Attention: Edward D. Yun
                    Telecopy: 617-753-1101

               with copies to:

                    Universal Hospital Services, Inc.

                                       39

<PAGE>

                    3800 West 80th Street, Suite 1250
                    Bloomington, Minnesota 55431-4442
                    Attention: Chief Executive Officer
                    Facsimile No.: 952-893-3232

                    Universal Hospital Services, Inc.
                    3800 West 80th Street, Suite 1250
                    Bloomington, Minnesota 55431-4442
                    Attention: David E. Dovenberg
                    Facsimile No.: 952-893-3232

                    Dorsey & Whitney LLP
                    50 South Sixth Street
                    Minneapolis, Minnesota 55402
                    Attention: Elizabeth C. Hinck, Esq.
                    Facsimile No.: 612-340-8738

          (b)  For notices and communications to the Stockholders, to the
     respective addresses or telecopy numbers set forth in the Schedule of
     Stockholders.

          (c)  With a copy in the case of the JWC Holders and the Company to:

                    Kaye Scholer LLP
                    425 Park Avenue
                    New York, NY 10022
                    Attention: Stephen C. Koval, Esq.
                    Fax: 212-836-8689

          (d)  With a copy in the case of the Halifax Holders and the Company
     to:

                    The Halifax Group
                    1133 Connecticut Avenue, N.W.
                    Suite 725
                    Washington, D.C. 20036
                    Attention: David W. Dupree
                    Facsimile No.: 202-296-7133

                    The Halifax Group
                    200 Crescent Court
                    Suite 1040
                    Dallas, Texas 75205

                                       40

<PAGE>

                    Attention: Brent D. Williams
                    Facsimile No.: 214-855-8712

          (e)  With a copy in the case of the Halifax Holders and the Company
     to:

                    Latham & Watkins LLP
                    555 11/th/ St. NW
                    Washington, DC 20004
                    Attention: James R. Hanna, Esq.
                    Facsimile No.: 202-637-2201

          (f)  With a copy in the case of the Management Holders to:

                    Universal Hospital Services, Inc.
                    3800 West 80th Street, Suite 1250
                    Bloomington, Minnesota 55431-4442
                    Attention: Chief Financial Officer
                    Facsimile No.: 952-893-3237

By notice complying with the foregoing provisions of this Section 7.4, each
party shall have the right to change the mailing address or telecopy numbers for
future notices and communications to such Party.

     6.5  Binding Effect; Assignment. This Agreement shall be binding upon and
inure to the benefit of the parties hereto and to their respective transferees,
successors, assigns, heirs and administrators, provided that the rights under
this Agreement may not be assigned except as expressly provided herein. No such
assignment shall relieve an assignor of its obligations hereunder.

     6.6  Termination. Without affecting any other provision of this Agreement
requiring termination of any rights in favor of any Stockholder, Permitted
Transferee or any other transferee of Common Stock Equivalents, the provisions
of Articles III and IV (other than the indemnity and contribution provisions set
forth therein) of this Agreement shall terminate as to such Stockholder,
Permitted Transferee or other transferee, when, pursuant to and in accordance
with this Agreement, such Stockholder, Permitted Transferee or other transferee,
as the case may be, no longer owns any Common Stock Equivalents.

     6.7  Recapitalizations, Exchanges, etc. The provisions of this Agreement
shall apply, to the full extent set forth herein with respect to Common Stock
Equivalents, to any and all shares of capital stock of the Company or any
successor or assign of the Company (whether by merger, consolidation, sale of
assets or otherwise) which may be issued in respect of, in exchange for, or in
substitution of the Common Stock Equivalents, by reason of a stock dividend,
stock split, stock issuance, reverse stock split, combination,

                                       41

<PAGE>

recapitalization, reclassification, merger, consolidation or otherwise. Upon the
occurrence of any such events, amounts hereunder shall be appropriately
adjusted.

     6.8  JWC Representative. Each JWC Holder hereby designates and appoints
(and each Permitted Transferee of each such JWC Holder shall be deemed to have
so designated and appointed) Steven G. Segal and Edward D. Yun (so long as they
are employees of J.W. Childs Associates, Inc. or its Affiliates or successor
entities), or either of them, with full power of substitution (the "JWC
Representative") the representative of each such Person to perform all such acts
as are required, authorized or contemplated by this Agreement to be performed by
any such Person and hereby acknowledges that the JWC Representative shall be the
only Person authorized to take any action so required, authorized or
contemplated by this Agreement by each such Person. Each such Person further
acknowledges that the foregoing appointment and designation shall be deemed to
be coupled with an interest and shall survive the death or incapacity of such
Person. Each such Person hereby authorizes (and each Permitted Transferee of
each such Person shall be deemed to have authorized) the other parties hereto to
disregard any notice or other action taken by such Person pursuant to this
Agreement except for the JWC Representative. The other parties hereto are and
will be entitled to rely on any action so taken or any notice given by the JWC
Representative and are and will be entitled and authorized to give notices only
to the JWC Representative for any notice contemplated by this Agreement to be
given to any such Person. A successor to the JWC Representative may be chosen by
the holders of a majority of the Common Stock Equivalents at the time held by
the JWC Holders, provided that written notice thereof is given by the successor
JWC Representative to the Company, the Halifax Holders, the Management Holders,
the Additional Holders and the other JWC Holders.

     6.9  Halifax Representative. Each Halifax Holder hereby designates and
appoints (and each Permitted Transferee of each such Halifax Holder shall be
deemed to have so designated and appointed) David W. Dupree and Brent D.
Williams (so long as they are employees of Halifax Capital Partners or its
Affiliates or successor entities), or either of them, with full power of
substitution (the "Halifax Representative") the representative of each such
Person to perform all such acts as are required, authorized or contemplated by
this Agreement to be performed by any such Person and hereby acknowledges that
the Halifax Representative shall be the only Person authorized to take any
action so required, authorized or contemplated by this Agreement by each such
Person. Each such Person further acknowledges that the foregoing appointment and
designation shall be deemed to be coupled with an interest and shall survive the
death or incapacity of such Person. Each such Person hereby authorizes (and each
Permitted Transferee of each such Person shall be deemed to have authorized) the
other parties hereto to disregard any notice or other action taken by such
Person pursuant to this Agreement except for the Halifax Representative. The
other parties hereto are and will be entitled to rely on any action so taken or
any notice given by the Halifax Representative and are and will be entitled and
authorized to give notices only to the Halifax Representative for any notice
contemplated by this Agreement to be given to any such Person. A successor to
the Halifax Representative may be chosen by the holders of a majority of the
Common Stock Equivalents at the time held by the Halifax Holders, provided that
written notice thereof is given by the

                                       42

<PAGE>

successor Halifax Representative to the Company, the JWC Holders, the Management
Holders, the Additional Holders and the other Halifax Holders.

     6.10 Action Necessary to Effectuate the Agreement. The parties hereto
agree to take or cause to be taken all such corporate and other action as may be
necessary to effect the intent and purposes of this Agreement.

     6.11 No Waiver. No course of dealing and no delay on the part of any party
hereto in exercising any right, power or remedy conferred by this Agreement
shall operate as waiver thereof or otherwise prejudice such party's rights,
powers and remedies. No single or partial exercise of any rights, powers or
remedies conferred by this Agreement shall preclude any other or further
exercise thereof or the exercise of any other right, power or remedy.

     6.12 Counterparts. This Agreement may be executed in two or more
counterparts (including Joinder Agreements as counterparts), each of which shall
be deemed an original, but all of which together shall constitute one and the
same instrument, and all signatures need not appear on any one counterpart. Any
counterpart or other signature hereupon delivered by facsimile shall be deemed
for all purposes as constituting good and valid execution and delivery of this
Agreement by such party. The failure of any Stockholder to execute this
Agreement does not make it invalid as against any other Stockholder.

     6.13 Headings, etc. All headings and captions in this Agreement are for
purposes of references only and shall not be construed to limit or affect the
substance of this Agreement. Words used in this Agreement, regardless of the
gender and number used, will be deemed and construed to include any other
gender, masculine, feminine, or neuter, and any other number, singular or
plural, as the context requires. As used in this Agreement, the word "including"
is not limiting, and the word "or" is not exclusive. The words "this Agreement",
"hereto", "herein", "hereunder", "hereof", and words or phrases of similar
import refer to this Agreement as a whole, together with any and all Schedules
and Exhibits hereto, and not to any particular article, section, subsection,
paragraph, clause or other portion of this Agreement.

     6.14 Governing Law; Jurisdiction; Service of Process. This Agreement shall
be governed by the laws of the State of Delaware, without regard to any
conflicts of laws principles thereof that would call for the application of the
laws of any other jurisdiction. Any action or proceeding seeking to enforce any
provision of, or based on any right arising out of, this Agreement may be
brought against either of the parties in the courts of the State of New York, or
if it has or can acquire jurisdiction, in the United States District Court for
the Southern District of New York, and each of the parties hereby consents to
the jurisdiction of such courts (and of the appropriate appellate courts) in any
such action or proceeding and waives any objection to venue laid therein.
Process in any action or proceeding referred to in the preceding sentence may be
served on any party anywhere in the world, whether within or without the State
of New York.

                                       43

<PAGE>

     6.15 Reproduction of Documents. This Agreement and all documents relating
thereto, including, without limitation, (i) consents, waivers and modifications
which may hereafter be executed and (ii) documents received by each Stockholder
or the Company pursuant hereto, may be reproduced by each party hereto by a
photographic, photostatic, microfilm, microcard, miniature photographic or other
similar process and each party may destroy any original document so reproduced.
All parties hereto agree and stipulate that any such reproduction shall be
admissible in evidence as the original itself in any judicial or administrative
proceeding (whether or not the original is in existence and whether or not such
reproduction was made by each party in the regular course of business) and that
any enlargement, facsimile or further reproduction of such reproduction shall
likewise be admissible in evidence.

     6.16 Confidentiality; Public Announcements. No Management Holder or
Additional Holder shall disclose or use in any manner whatsoever, in whole or in
part, any information concerning the Company or any of its direct or indirect
stockholders, or any of their respective employees, directors or Subsidiaries or
Affiliates (including, without limitation, the JWC Holders) received on a
confidential basis from the Company or any other Person under or pursuant to
this Agreement or any other agreement with the Company including without
limitation financial terms and financial and organizational information
contained in any documents, statements, certificates, materials or information
furnished, or to be furnished, by or on behalf of the Company or any other
Person in connection with the purchase or ownership of any Common Stock
Equivalent; provided, however, that the foregoing shall not be construed, now or
in the future, to apply to any information reflected in any recorded document,
information which is independently developed by such Stockholder, information
obtained from sources other than the Company or any of its direct or indirect
shareholders, or any of their respective employees, directors, Subsidiaries or
Affiliates (including without limitation the JWC Holders) or any of their
respective agents or representatives (including without limitation attorneys,
accountants, financial advisors, engineers and insurance brokers) or information
that is or becomes in the public domain, nor shall it be construed to prevent
such Stockholder from (i) making any disclosure of any information (a) if
required to do so by any statute, law, treaty, rule, regulation, order, decree,
writ, injunction or determination of any court or other governmental authority,
in each case applicable to or binding upon such Stockholder, (b) to any
governmental authority having or claiming authority to regulate or oversee any
aspect of such Stockholder's business or that of the corporate parent or
affiliates of such Stockholder in connection with the exercise of such authority
or claimed authority, or (c) pursuant to subpoena; or (ii) making, on a
confidential basis, such disclosures as such Stockholder deem necessary or
appropriate to such Stockholder's legal counsel, accountants (including outside
auditors) or general, managing or limited partners; (iii) making such
disclosures as such Stockholder reasonably deems necessary or appropriate to any
Transferee and/or counsel to or other representatives of such bank or financial
institution or other entity, to which such Stockholder in good faith desires to
Transfer all or a portion of its interest in any Common Stock Equivalents;
provided, however, that such Transferee or counsel to or representative thereof
, agrees to maintain the confidentiality of such disclosures on the terms stated
herein; or (iv) making, on a confidential basis, disclosures of such information
to current Stockholders; provided, further, that this Section 7.16 shall not
supersede any confidentiality provision in any employment agreement or
confidentiality agreement to which any Management Holder is a party for so long
as such agreement remains in effect. Notwithstanding anything to the contrary,
(A) this Section 7.16 shall apply to the JWC

                                       44

<PAGE>

Holders and/or the Halifax Holders (as applicable) effective at such time when
such group shall no longer have the right to designate directors to the Board of
Directors of the Company pursuant to Article V hereof and (B) the parties hereto
and each of their respective employees, representatives or other agents, are
permitted to disclose to any and all persons, without limitations of any kind,
the tax treatment and tax structure of any transactions entered into among the
parties and all materials of any kind (including opinions or other tax analyses)
that are or have been provided to such parties related to such tax treatment and
tax structure; provided, however, that the foregoing permission to disclose the
tax treatment and tax structure does not permit the disclosure of any
information that is not relevant to understanding the tax treatment or tax
structure of any such transactions (including the identity of any party and the
amounts paid in connection with the transactions); provided, further, however,
that the tax treatment and tax structure shall be kept confidential to the
extent necessary to comply with federal or state securities laws.

                         [Signatures on Following Pages]

                                       45

<PAGE>

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first set forth above.

                              THE COMPANY:

                              UNIVERSAL HOSPITAL SERVICES, INC.

                              By: /s/ Gary D. Blackford
                                  --------------------------------------------
                                  Name:  Gary D. Blackford
                                  Title: President and Chief Executive Officer

<PAGE>

                   Amended and Restated Stockholders Agreement

                   Continuation of Counterpart Signature Pages
                   -------------------------------------------

                            J.W. CHILDS EQUITY PARTNERS III, L.P.

                            By:  J.W. Childs Advisors III, L.P., General Partner
                            By:  J.W. Childs Associates, L.P., General Partner
                            By:  J.W. Childs Associates, Inc., General Partner

                            By:  /s/ Steven G. Segal
                               -------------------------------
                                 Name:  STEVEN G. SEGAL
                                 Title: VICE PRESIDENT

                            JWC FUND III CO-INVEST, LLC

                            By:  J.W. Childs Associates, L.P., Manager
                            By:  J.W. Childs Associates, Inc., General Partner

                            By:  /s/ Steven G. Segal
                               ------------------------------
                               Name:  STEVEN G. SEGAL
                               Title: VICE PRESIDENT

                            J.W. CHILDS EQUITY PARTNERS, L.P.

                            By:  J.W. Childs Advisors, L.P., General Partner
                            By:  J.W. Childs Associates, L.P., General Partner
                            By:  J.W. Childs Associates, Inc., General Partner

                            By:  /s/ Steven G. Segal
                               ----------------------------
                               Name:  STEVEN G. SEGAL
                               Title: VICE PRESIDENT

     By executing above, the foregoing JWC Holder acknowledges that, pursuant to
Section 7.8 of this Amended and Restated Stockholders Agreement, the foregoing
JWC Holder has designated and appointed Steven G. Segal and Edward D. Yun, or
either of them, as its representative to perform all acts as are required,
authorized or contemplated by this Stockholders Agreement Amended and Restated
Stockholders Agreement

<PAGE>

                   Amended and Restated Stockholders Agreement

                   Continuation of Counterpart Signature Pages
                   -------------------------------------------

                            JWC-UHS CO-INVEST LLC

                            By:  J.W. Childs Associates, Inc., Manager

                            By:  /s/ Ted D. Yun
                               -----------------------------
                               Name: Ted D. Yun
                               Title: Partner

     By executing above, the foregoing JWC Holder acknowledges that, pursuant to
Section 7.8 of this Amended and Restated Stockholders Agreement, the foregoing
JWC Holder has designated and appointed Steven G. Segal and Edward D. Yun, or
either of them, as its representative to perform all acts as are required,
authorized or contemplated by this Stockholders Agreement Amended and Restated
Stockholders Agreement

<PAGE>

                   Amended and Restated Stockholders Agreement

                   Continuation of Counterpart Signature Pages
                   -------------------------------------------

                            THE HALIFAX HOLDERS:

                            HALIFAX CAPITAL PARTNERS, L.P.
                            By:  Halifax Genpar, L.P.
                            By:  The Halifax Group, L.L.C.

                            By:  /s/ Brent D. Williams
                               ----------------------------------
                               Name: Brent D. Williams
                               Title: Principal, Vice President

     By executing above, each of the foregoing Halifax Holders acknowledges
that, pursuant to Section 7.9 of this Amended and Restated Stockholders
Agreement, each of the foregoing Halifax Holders has designated and appointed
David W. Dupree and Brent D. Williams, or either of them, as its representative
to perform all acts as are required, authorized or contemplated by this Amended
and Restated Stockholders Agreement

<PAGE>

                   Amended and Restated Stockholders Agreement

                   Continuation of Counterpart Signature Pages
                   -------------------------------------------

                            MANAGEMENT HOLDERS:

                                   /s/ Gary D. Blackford
                                   ----------------------------
                                   GARY D. BLACKFORD

<PAGE>

                        UNIVERSAL HOSPITAL SERVICES,INC.

                   Amended and Restated Stockholders Agreement

                   Continuation of Counterpart Signature Pages
                   -------------------------------------------

                               ADDITIONAL HOLDERS:

                                   MANAGEMENT HOLDERS:

                                   /s/ David E. Dovenberg
                                   ------------------------------
                                   Name: David E. Dovenberg

Signature Page

<PAGE>

                                    EXHIBIT A

                            SCHEDULE OF STOCKHOLDERS

J.W. Childs Equity Partners III, L.P.

JWC Fund III Co-invest LLC

J.W. Childs Equity Partners, L.P.

JWC-UHS Co-Invest LLC

Halifax Capital Partners, L.P.

Gary D. Blackford

David E. Dovenberg

<PAGE>

                                    EXHIBIT B

                                JOINDER AGREEMENT

     The undersigned is executing and delivering this Joinder Agreement pursuant
to the Amended and Restated Stockholders Agreement, dated as of October ___,
2003 (the "Stockholders Agreement"), among Universal Hospital Services, Inc., a
Delaware corporation (the "Company"), the JWC Holders, the Halifax Holders, the
Management Holders and the Additional Holders named therein.

     By executing and delivering this Joinder Agreement to the Company, the
undersigned hereby agrees to become a party to, to be bound by, and to comply
with the provisions of the Stockholders Agreement in the same manner as if the
undersigned were an original signatory to such agreement as a
[JWC/Halifax/Additional/Management] Holder. In connection therewith, effective
as of the date hereof the undersigned hereby makes the representations and
warranties contained in the Stockholders Agreement.

     Accordingly, the undersigned has executed and delivered this Joinder
Agreement as of the __ day of ____________, _____.

                                        ----------------------------------------
                                        Signature of Stockholder

                                        ----------------------------------------
                                        Print Name of Stockholder

<PAGE>

                                    EXHIBIT C

                          INDEPENDENT FINANCIAL EXPERTS

1.   Goldman, Sachs & Co.
2.   Credit Suisse First Boston
3.   J.P. Morgan Chase & Co.
4.   Lehman Brothers
5.   Bank of America<PAGE>

                                                                    Exhibit 10.6

                                October 17, 2003

Mr. David E. Dovenberg
Universal Hospital Services, Inc.
1250 Northland Plaza
3800 West 80/th/ Street
Bloomington, MN 55431

Dear Mr. Dovenberg:

     You currently serve as Chairman of the Board of Directors of Universal
Hospital Services, Inc. (the "Company") pursuant to that certain employment
agreement dated as of July 25, 2001 (as amended by resolution of the Board of
Directors on June 25, 2002, the "2001 Employment Agreement"). As of January 1,
2004 (the "Effective Date"), this Employment Agreement replaces the 2001
Employment Agreement and sets forth the agreed terms of your employment with the
Company beginning as of the Effective Date. Prior to the Effective Date, the
terms of your employment will continue to be governed by the 2001 Employment
Agreement.

     For good and valuable consideration, the parties hereto agree as follows:

     1.   Position; Duties. The Company agrees to employ you, and you agree to
serve and accept employment, for the Term (as defined below) as non-executive
Chairman of the Board of the Company, subject to the direction and control of
the Board of Directors of the Company (the "Board"), and, in connection
therewith, to perform such other duties as the Board may from time to time
reasonably direct. Your place of employment will be in the Minneapolis,
Minnesota area. You will not be given duties inconsistent with your position.

     2.   Term of Employment Agreement. The term of your employment hereunder
will begin as of the Effective Date and end as of the close of business on the
Date of Termination (as defined in Section 4(g)) (the "Term").

     3.   Compensation and Benefits.

     (a)  Base Salary. Your base salary will be at annual rate of for the
applicable year as set forth below, payable in equal bi-weekly installments.
Necessary withholding taxes, FICA contributions and the like will be deducted
from your base salary.

     Fiscal Year          Annual Base Salary
----------------------    ------------------
2004                      $          150,000
2005                      $          125,000
2006 through June 2009    $          100,000

<PAGE>

Mr. David E. Dovenberg
Page 2
October 17, 2003

     (b)  Bonus. You will be entitled to receive such bonus payment as is
payable with respect to the fiscal year ending December 31, 2003 in accordance
with the 2001 Employment Agreement. Thereafter, you will not be entitled to
participate in the Company's executive or other employee bonus plans.

     (c)  Other. You will be entitled to such health (including dental), life
and disability benefits as are generally made available by the Company to its
executive employees. You will not be entitled to any other benefits that are
generally made available by the Company to its executive employees.

     4.   Termination.

     (a)  Death. This Employment Agreement will automatically terminate upon
your death. In the event of such termination, the Company's obligations
hereunder will terminate with no further payments or severance.

     (b)  Disability. If during the Term you become physically or mentally
disabled, whether totally or partially, either permanently or so that you are
unable substantially and competently to perform your duties hereunder for a
period of 90 consecutive days or for 90 days during any six-month period during
the Term (a "Disability"), the Company may terminate your employment hereunder
by written notice to you. In the event of such termination, the Company will pay
to you the amount of $100,000 annually (the "Severance Amount") and continue to
provide the benefits provided hereunder, in each case from the Date of
Termination until June 30, 2009 (the "Severance Period").

     (c)  Cause. Your employment hereunder may be terminated at any time by the
Company for Cause (as defined herein) by written notice to you. In the event of
such termination, all of your rights to payments (other than payment for
services already rendered) and any other benefits otherwise due hereunder will
cease immediately. The Company will have "Cause" for termination of your
employment hereunder if any of the following has occurred.

               (i)   your continued failure, whether willful, intentional or
          grossly negligent, after written notice, to perform substantially your
          duties hereunder (other than as a result of a Disability);

               (ii)  dishonesty in the performance of your duties hereunder;

               (iii) conviction or confession of an act or acts on your part
          constituting a felony under the laws of the United States or any state
          thereof;

<PAGE>

Mr. David E. Dovenberg
Page 3
October 17, 2003

               (iv)  any other willful act or omission on your part which is
          materially injurious to the financial condition or business reputation
          of the Company or any of its subsidiaries;

               (v)   you have breached any provision of this Employment
          Agreement contained in Paragraphs 6, 7 and 8 hereof; or

               (vi)  you have breached any provision of this Employment
          Agreement (other than paragraphs 6, 7 or 8 hereof) and such breach
          will not have been cured within sixty days after notice thereof from
          the Company to you.

     (d)  Without Cause. Your employment hereunder may be terminated at any time
by the Company without Cause by written notice to you. In the event of such
termination, the Company will pay to you the Severance Amount and continue to
provide the benefits provided hereunder, in each case for the Severance Period;
provided, however, that if the Date of Termination with respect to such
termination by the Company pursuant to this Section 4(d) is on or after a Change
in Control (as defined below), then you will not be entitled to receive, nor
will the Company be obligated to pay, the Severance Amount, or any salary or
severance amount or continue any benefits hereunder, on or after such Date of
Termination. For purposes of this Agreement, a "Change in Control" shall mean
when any "person" (as defined in Section 13(d) and 14(d) of the Securities
Exchange Act of 1934), other than the Company, J.W. Childs Equity Partners,
L.P., J.W. Childs Equity Partners III, L.P., or any of their respective
affiliates, any trustee or other fiduciary holding securities under an employee
benefit plan of the Company or any of its subsidiaries, or any corporation
owned, directly or indirectly, by the stockholders of the Company, in
substantially the same proportions as their ownership of stock of the Company,
acquires, in a single transaction or a series of transactions (i) "beneficial
ownership" (as defined in Rule 13d-3 under the Securities Exchange Act of 1934)
of securities representing more than 50% of the combined voting power of the
Company (or, prior to a public offering, more than 50% of the Company's
outstanding shares of Common Stock), or (ii) substantially all of the assets of
the Company."

     (e)  Resignation Without Good Reason. You may terminate your employment
hereunder upon sixty days' prior written notice to the Company, without Good
Reason (as defined herein). In the event of such termination, all of your rights
to payment (other than payment for services already rendered) and any other
benefits otherwise due hereunder will cease upon the Date of Termination.

     (f)  Resignation For Good Reason. You may terminate your employment
hereunder at any time upon thirty days' written notice to the Company, for Good
Reason. In the event of such termination, the Company will continue to pay you
your base salary though the date which is eighteen months from the Date of
Termination; provided, however, that if the Date of

<PAGE>

Mr. David E. Dovenberg
Page 4
October 17, 2003

Termination with respect to such termination by you pursuant to this Section
4(f) is on or after a Change in Control, then you will not be entitled to
receive, nor will the Company be obligated to pay, any salary or severance
amount or continue any benefits hereunder on or after such Date of Termination.
You will have "Good Reason" for termination of your employment hereunder if,
other than for Cause, any of the following has occurred:

               (i)   your base salary has been reduced--(other than in
          connection with an across-the-board reduction (of approximately the
          same percentage) in executive compensation to Executive Employees
          imposed by the Board in response to negative financial results or
          other adverse circumstances affecting the Company;

               (ii)  the Company has required you to relocate outside the
          greater Minneapolis, Minnesota area;

               (iii) your illness, that in the good faith determination of the
          Board of Directors of the Company is likely to result in you becoming
          disabled and unable to continue your employment with the Company; or

               (iv)  the Company has breached this Employment Agreement in any
          material respect.

     (g)  Date and Effect of Termination. The date of termination of your
employment hereunder, pursuant to this Paragraph 4, will be, (i) in the case of
Paragraph 4(a), the date of your death, (ii) in the case of Paragraphs 4(b), (c)
or (d), the date specified as your last date of employment in the Company's
notice to you of such termination or (iii) in the case of Paragraph 4(e) or
4(f), the date specified in your notice to the Company of such termination (in
each case, the "Date of Termination"). Upon any termination of your employment
hereunder pursuant to this Paragraph 4, you will not be entitled to any further
payments or benefits of any nature pursuant to this Employment Agreement, or as
a result of such termination, except as specifically provided for in this
Employment Agreement, the Stockholders' Agreement between the Company and the
equity security holders of the Company, in any stock option plans adopted by the
Company in accordance with Paragraph 3(b) hereof, or as may be required by law.

     5.   Acknowledgment. You agree and acknowledge that in the course of
rendering services to the Company and its clients and customers, you will have
access to and become acquainted with confidential information about the
professional, business and financial affairs of the Company and its affiliates.
You acknowledge that the Company is engaged and will be engaged in a highly
competitive business, and the success of the Company in the marketplace depends
upon its good will and reputation for quality and dependability. You agree and
acknowledge that reasonable limits on your ability to engage in activities
competitive with the

<PAGE>

Mr. David E. Dovenberg
Page 5
October 17, 2003

Company are warranted to protect its substantial investment in developing and
maintaining its status in the marketplace, reputation and good will. You
recognize that in order to guard the legitimate interests of the Company and its
affiliates, it is necessary for the Company to protect all confidential
information. The existence of any claim or cause of action by you against the
Company shall not constitute and shall not be asserted as a defense to the
enforcement by the Company of this Employment Agreement. You further agree that
your obligations under Paragraphs 6, 7 and 8 hereof shall be absolute and
unconditional.

     6.   Confidentiality. You agree that during and at all times after the
Term, you will keep secret all confidential matters and materials of the Company
(including its subsidiaries and affiliates), including, without limitation,
know-how, trade secrets, real estate plans and practices, individual office
results, customer lists, pricing policies, operational methods, any information
relating to the Company (including any of its subsidiaries and affiliates)
products, processes, customers and services and other business and financial
affairs of the Company (collectively, the "Confidential Information"), to which
you had or may have access and will not disclose such Confidential Information
to any person other than the Company, their respective authorized employees and
such other person to whom you have been instructed to make disclosure by the
Board, in each case only to the extent required in the course of your service to
the Company hereunder or as otherwise expressly required in connection with
court process. "Confidential Information" will not include any information which
is in the public domain during or after the term, provided such information is
not in the public domain as a consequence of disclosure by you in violation of
this Employment Agreement.

     7.   Non-competition. During the Prohibition Period (as hereinafter
defined), you will not, in any capacity, whether for your own account or for any
other person or organization, directly or indirectly, within the United States
and Canada (a) own, operate, manage or control, (b) serve as an officer,
director, partner, employee, agent, consultant, advisor or developer or in any
similar capacity to, or (c) have any financial interest in, or aid or assist
anyone else in the conduct of, any person or enterprise which is engaged in a
business competitive with the activities of the business actually conducted by
the Company. As used herein, "Prohibition Period" means the period from and
after the date hereof to and including the later of (i) the last day of the Term
or (ii) the last day of the Severance Period.

     8.   Non-solicitation. During the Prohibition Period, you will not,
directly or indirectly, hire, recruit, solicit, call upon, divert, take away,
entice or in any other manner persuade or attempt to do any of the foregoing
with respect to, any employee, independent contractor, dealer, supplier, client,
customer or business contact of the Company or any of its subsidiaries to
discontinue his or her position or relationship, or violate any agreement, with
the Company or any of its subsidiaries as employee, independent contractor,
dealer, supplier, client,

<PAGE>

Mr. David E. Dovenberg
Page 6
October 17, 2003

customer or business contact, except with the prior written consent of the
Board, which consent will be given at the sole discretion of the Board.

     9.   Modification. You agree and acknowledge that the duration, scope and
geographic area of the covenants described in Paragraphs 6, 7 and 8 are fair,
reasonable and necessary in order to protect the good will and other legitimate
interest of the Company and its subsidiaries, that adequate consideration has
been received by you for such obligations, and that these obligations do not
prevent you from earning a livelihood. If, however, for any reason any court of
competent jurisdiction determines that any restriction contained in Paragraphs
6, 7 or 8 are not reasonable, that consideration is inadequate or that you have
been prevented unlawfully from earning a livelihood, such restriction will be
interpreted, modified or rewritten to include as much of the duration, scope and
geographic area identified in such Paragraphs 6, 7 or 8 as will render such
restrictions valid and enforceable.

     10.  Equitable Relief. You acknowledge that the Company will suffer
irreparable harm as a result of a breach of this Employment Agreement by you for
which an adequate monetary remedy does not exist and a remedy at law may prove
to be inadequate. Accordingly, in the event of any actual or threatened breach
by you of any provision of this Employment Agreement, the Company will, in
addition to any other remedies permitted by law, be entitled to obtain remedies
in equity, including without limitation specific performance, injunctive relief,
a temporary restraining order and/or a permanent injunction in any court of
competent jurisdiction, to prevent or otherwise restrain any such breach without
the necessity of proving damages, posting a bond or other security, and to
recover any and all costs and expenses, including reasonable counsel fees,
incurred in enforcing this Employment Agreement against you, and you hereby
consent to the entry of such relief against you and agree not to contest such
entry. Such relief will be in addition to and not in substitution of any other
remedies available to the Company. The existence of any claim or cause of action
by you against the Company or any of its subsidiaries, whether predicated on
this Employment Agreement or otherwise, will not constitute a defense to the
enforcement by the Company of this Employment Agreement. You agree not to defend
on the basis that there is an adequate remedy at law.

     11.  Successors; Assigns; Amendment; Notice. This Employment Agreement will
be binding upon and will inure to the benefit of the Company and will not be
assigned by the Company without your prior written consent. This Employment
Agreement will be binding upon you and will inure to the benefit of your heirs,
executors, administrators and legal representatives, but will not be assignable
by you. This Employment Agreement may be amended or altered only by the written
agreement of the Company and you. All notices or other communications permitted
or required under this Employment Agreement will be in writing and will be
deemed to have been duly given if delivered by hand, by facsimile transmission
to the Company (if confirmed) or mailed (certified or registered mail, postage
prepaid, return receipt

<PAGE>

Mr. David E. Dovenberg
Page 7
October 17, 2003

requested) to you or the Company at the respective addresses on the first page
of this Employment Agreement, or such other address as will be furnished in
writing by like notice by you or the Company to the other.

     12.  Entire Agreement. This Employment Agreement embodies the entire
agreement and understanding between you and the Company with respect to the
subject matter hereof and supersedes all such prior agreements and
understandings.

     13.  Severability. If any term, provision, covenant or restriction of this
Employment Agreement is held by a court of competent jurisdiction to be invalid,
void or unenforceable, the remainder of the terms, provisions, covenants and
restrictions of this Employment Agreement will remain in full force and effect
and will in no way be affected, impaired or invalidated.

     14.  Governing Law. This Employment Agreement will be governed by and
construed and enforced in accordance with the laws of state of Minnesota
applicable to contracts made and to be performed in such state without giving
effect to the principles of conflicts of laws thereof.

     15.  Counterparts. This Employment Agreement may be executed in two or more
counterparts, each of which will be deemed an original but all of which together
will constitute one and the same instrument, and all signatures need not appear
on any one counterpart.

     16.  Headings. All headings in this Employment Agreement are for purposes
of reference only and will not be construed to limit or affect the substance of
this Employment Agreement.

<PAGE>

Mr. David E. Dovenberg
Page 8
October 17, 2003

     If you accept and agree to the foregoing, please sign and return a
counterpart of this letter to the Company at the above address, whereupon this
letter will become a binding Employment Agreement between you and the Company as
of the date hereof.

                                        Very truly yours,

                                        UNIVERSAL HOSPITAL SERVICES, INC.

                                        By: /s/ Gary D. Blackford
                                           -------------------------------------
                                        Name: Gary D. Blackford
                                             -----------------------------------
                                        Title: President and Chief Executive
                                              ----------------------------------
                                               Officer
                                              ----------------------------------

Accepted and agreed to:

/s/ David E. Dovenberg
----------------------------------
David E. Dovenberg

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00058-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00058-of-00352.parquet"}]]